{"id":54750,"date":"2026-04-14T18:13:27","date_gmt":"2026-04-14T10:13:27","guid":{"rendered":"https:\/\/biopioneer.com.tw\/?p=54750"},"modified":"2026-04-14T18:13:27","modified_gmt":"2026-04-14T10:13:27","slug":"p-cresyl-sulfate-cas3233-58-7-apexbio%e8%b2%a8%e8%99%9fa8895","status":"publish","type":"post","link":"https:\/\/biopioneer.com.tw\/?p=54750","title":{"rendered":"p-Cresyl sulfate | CAS#3233-58-7 APExBIO\u8ca8\u865fA8895"},"content":{"rendered":"

MAPK\/ERK Pathway\u7cfb\u5217\u5546\u54c1->>p-Cresyl sulfate<\/span>
\n<\/span><\/span><\/span><\/strong><\/p>\n

APExBIO Technology LLC \u662f\u4e00\u5bb6\u9818\u5148\u7684\u5c0f\u5206\u5b50\u6291\u5236\u5291 (Small Molecule Inhibitors)\/\u6d3b\u5316\u5291(Activators)\u3001\u5316\u5408\u7269\u5eab( Compound Libraries)\u3001\u80dc\u80bd(Peptides)\u3001\u6aa2\u6e2c\u8a66\u5291\u76d2(Assay Kits)\u3001\u87a2\u5149\u6a19\u8a18(Fluorescent Label)\u3001\u9176(Enzymes)\u3001\u4fee\u98fe\u6838\u82f7\u9178(Modified Nucleotides)\u3001mRNA \u5408\u6210\u4ee5\u53ca\u5404\u7a2e\u5206\u5b50\u751f\u7269\u5b78\u5de5\u5177\u7684\u4f9b\u61c9\u5546\u3002APExBIO\u63d0\u4f9b\u5ee3\u6cdb\u7684\u7522\u54c1\u7dda\uff0c\u6db5\u84cb 20 \u591a\u500b\u4e0d\u540c\u7684\u7814\u7a76\u9818\u57df\uff0c\u4f8b\u5982\u764c\u75c7(cancer)\u3001\u514d\u75ab\u5b78(immunology)\u3001\u795e\u7d93\u79d1\u5b78(neurosciences)\u3001\u7d30\u80de\u51cb\u4ea1(apoptosis)\u548c\u8868\u89c0\u907a\u50b3\u5b78(epigenetics)\u7b49\u3002\u516c\u53f8\u7e3d\u90e8\u4f4d\u65bc\u7f8e\u570b\u5fb7\u5dde\u4f11\u58eb\u9813USA (Houston, Texas)\uff0c\u81f4\u529b\u65bc\u670d\u52d9\u5168\u7403\u5ba2\u6236\u3002\u9ad8\u5ea6\u91cd\u8996\u7522\u54c1\u54c1\u8cea\u3002\u6240\u6709\u7522\u54c1\u5747\u9075\u5faa\u56b4\u683c\u7684\u751f\u7522\u6307\u5357\uff0c\u4e26\u9644\u6709\u5206\u6790\u8b49\u66f8\u3001HPLC\u3001\u8cea\u8b5c(Mass Spectrum)\u548cHMNR\u4ee5\u53ca\u9ad4\u5916\u9a57\u8b49(in vitro validation)\u3002 APExBIO\u7522\u54c1\u5df2\u88ab\u300aNature\u300b\u3001\u300aCell\u300b\u548c\u300aScience\u300b\u7b49\u773e\u591a\u9802\u7d1a\u540c\u884c\u8a55\u5be9\u671f\u520a\u5f15\u7528\u3002>>\u66f4\u591aAPExBio\u5546\u54c1<\/span><\/strong><\/em><\/span><\/a><\/p>\n

<\/p>\n

p-Cresyl sulfate | CAS#3233-58-7 APExBIO\u8ca8\u865fA8895<\/span><\/strong><\/span><\/a><\/span><\/p>\n

Protein-bound uremic retention solute<\/span><\/p>\n

\u5c0d\u7532\u915a\u786b\u9178\u916f ( p-Cresyl sulfate ) \uff08CAS 3233-58-7\uff09\u662f\u4e00\u7a2e\u7531\u5c0d\u7532\u915a\u884d\u751f\u7684\u86cb\u767d\u7d50\u5408\u578b\u5c3f\u6bd2\u75c7\u6eef\u7559\u6eb6\u8cea\uff0c\u8207\u63a5\u53d7\u900f\u6790\u6cbb\u7642\u7684\u6162\u6027\u814e\u81df\u75c5\u60a3\u8005\u7684\u5fc3\u8840\u7ba1\u98a8\u96aa\u5bc6\u5207\u76f8\u95dc\u3002\u8840\u6db2\u900f\u6790\u60a3\u8005\u9ad4\u5167\u6e38\u96e2\u5c0d\u7532\u915a\u786b\u9178\u916f\u6fc3\u5ea6\u5347\u9ad8\u8207\u5fc3\u8840\u7ba1\u75be\u75c5\u767c\u751f\u7387\u589e\u52a0\u5bc6\u5207\u76f8\u95dc\u3002\u5f9e\u6a5f\u5236\u4e0a\u8b1b\uff0c\u5c0d\u7532\u915a\u786b\u9178\u916f ( p-Cresyl sulfate )\u6291\u5236\u5167\u76ae\u7d30\u80de\u589e\u6b96\u4e26\u640d\u5bb3\u50b7\u53e3\u7652\u5408\uff0c\u4f46\u4e0d\u5f71\u97ff\u7d30\u80de\u6d3b\u529b\uff0c\u5f9e\u800c\u53ef\u80fd\u52a0\u5287\u8840\u7ba1\u4f75\u767c\u75c7\u3002\u7531\u65bc\u5176\u5728\u5167\u76ae\u529f\u80fd\u969c\u7919\u548c\u5fc3\u8840\u7ba1\u4e8b\u4ef6\u4e2d\u7684\u4f5c\u7528\uff0c\u5c0d\u7532\u915a\u786b\u9178\u916f ( p-Cresyl sulfate )\u88ab\u7528\u4f5c\u5c3f\u6bd2\u75c7\u76f8\u95dc\u5fc3\u8840\u7ba1\u7814\u7a76\u7684\u751f\u7269\u6a19\u8a18\u3002<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
Physical Appearance<\/td>\nA solid<\/td>\n<\/tr>\n
Storage<\/td>\nStore at -20\u00b0C
\nThe product is not stable in solution, please dissolve it immediately before use.<\/td>\n<\/tr>\n
M.Wt<\/td>\n188.20<\/td>\n<\/tr>\n
Cas No.<\/td>\n3233-58-7<\/td>\n<\/tr>\n
Formula<\/td>\nC7<\/sub>H8<\/sub>O4<\/sub>S<\/td>\n<\/tr>\n
Solubility<\/td>\ninsoluble in EtOH; \u226530.1 mg\/mL in DMSO; \u226550 mg\/mL in H2O<\/td>\n<\/tr>\n
Chemical Name<\/td>\np-tolyl hydrogen sulfate<\/td>\n<\/tr>\n
Canonical SMILES<\/td>\nCc(cc1)ccc1OS(O)(=O)=O<\/td>\n<\/tr>\n
Shipping Condition<\/td>\nSmall Molecules with Blue Ice, Modified Nucleotides with Dry Ice.<\/td>\n<\/tr>\n
General tips<\/td>\nWe do not recommend long-term storage for the solution, please use it up soon.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

<\/p>\n

\"\u7db2\u7ad9\u898f\u683c\u5c0f\u5716_\u5de5\u4f5c\u5340\u57df<\/a><\/p>\n\n\n\n\n\n\n\n\n\n\n\n
\u54c1\u9805<\/td>\nCAS#<\/td>\n#\u8ca8\u865f<\/td>\n\u61c9\u7528<\/td>\n<\/tr>\n
Romidepsin (FK228, depsipeptide)<\/a><\/td>\n\n

CAS#128517-07-7<\/p>\n

 <\/td>\n

\u8ca8\u865fA8173<\/td>\nHDAC1\/HDAC2\uff0c\u5f37\u6548\u548c\u9078\u64c7\u6027\u6291\u5236\u5291<\/td>\n<\/tr>\n
Pirarubicin<\/a><\/td>\nCAS#72496-41-4<\/td>\n\u8ca8\u865fB2295<\/td>\n\u00a0anthracycline anti-neoplastic doxorubicin<\/td>\n<\/tr>\n
Tunicamycin<\/a><\/td>\nCAS# 15663-27-1<\/td>\n\n

\u8ca8\u865fA8321<\/p>\n

 <\/td>\n

\u9ad8\u6548\u3001\u5ee3\u8b5c\u7684\u5316\u7642\u85e5\u7269<\/td>\n<\/tr>\n
Azithromycin<\/a><\/td>\nCAS#83905-01-5<\/td>\n\u00a0\u8ca8\u865fA2213<\/td>\nHsp90 inhibitor<\/td>\n<\/tr>\n
Bleomycin Sulfate<\/a><\/td>\n\n

CAS# 9041-93-4<\/p>\n

 <\/td>\n

\u8ca8\u865fB1398<\/td>\nAntibiotic by inhibiting protein synthesis<\/td>\n<\/tr>\n
Nystatin (Fungicidin)<\/a><\/td>\nCAS#1400-61-9<\/td>\n\u8ca8\u865fB1993<\/td>\nantifungal antibiotic<\/td>\n<\/tr>\n
Rapamycin<\/a><\/td>\nCAS#53123-88-9<\/td>\n\u8ca8\u865fA8167<\/td>\nOriginal antifungal antibiotic<\/td>\n<\/tr>\n
Daptomycin<\/a><\/td>\nCAS#103060-53-3<\/td>\n\u8ca8\u865fA1206<\/td>\nCalcium-dependent antibiotic<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

<\/p>\n

\"APExBIO_logo\"<\/a><\/p>\n

APExBIO\u53f0\u7063\u4ee3\u7406\u5546:\u00a0 <\/span><\/span><\/strong><\/span><\/a>https:\/\/www.apexbt.com\/<\/span><\/span><\/a><\/span><\/p>\n

APExBIO\u63d0\u4f9b\u512a\u8cea\u7684\u80dc\u80bd\u548c\u751f\u7269\u5206\u6790\u8a66\u5291\uff0c\u5ee3\u6cdb\u7522\u54c1\u7dda\u5982Protease\u3001Chromatin\/Epigenetics\u8868\u89c0\u907a\u50b3\u5b78\u3001MAPK Signal\u3001DNA Damege\/DNA repair\u3001\u7d30\u80de\u51cb\u4ea1\u3001\u816b\u7624\u751f\u7269\u5b78\u3001Stem cell\u7b49\u7814\u7a76\u9818\u57df\uff0c \u9084\u63d0\u4f9b\u5b9a\u5236\u7684\u670d\u52d9\uff0c\u5305\u62ec\u591a\u80bd\u5408\u6210\uff0c\u6297\u9ad4\u7684\u751f\u7522\u548c\u6aa2\u6e2c\u7684\u767c\u5c55\u3002\u7522\u54c1\u7ddaDNA\/RNA prep kit\u3001Drug Screening panel\u3001Bioactive peptides\u3001Growth factors\u3001Biotinylation Reagents\u3001tag peptides\u3001amino Acids\u3001Growth factors\u7b49\u3002APExBIO\u7522\u54c1\u8cea\u91cf\u90fd\u4f34\u96a8\u8457\u8b49\u66f8\u7684\u5206\u6790\uff0c\u9ad8\u6548\u6db2\u76f8\u8272\u8b5c\uff0c\u8cea\u8b5c\uff0c\u548cHMNR\u6578\u64da\u3002>>\u66f4\u591aAPExBio\u5546\u54c1<\/span><\/strong><\/em><\/span><\/a><\/p>\n

<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Cat#<\/td>\nProduct Name<\/td>\n<\/tr>\n
A8743<\/td>\nSYBR Safe DNA Gel Stain<\/td>\n<\/tr>\n
A6001<\/td>\n3X (DYKDDDDK) Peptide<\/td>\n<\/tr>\n
K1018<\/td>\nCell Counting Kit-8 (CCK-8)<\/td>\n<\/tr>\n
A1902<\/td>\nZ-VAD-FMK<\/td>\n<\/tr>\n
A3008<\/td>\nY-27632 dihydrochloride<\/td>\n<\/tr>\n
A6002<\/td>\nDYKDDDDK tag Peptide<\/td>\n<\/tr>\n
B8362<\/td>\n2’3′-cGAMP (sodium salt)<\/td>\n<\/tr>\n
F4002<\/td>\nPhos binding reagent (Phosbind) acrylamide<\/td>\n<\/tr>\n
A8011<\/td>\nBiotin-tyramide<\/td>\n<\/tr>\n
A2585<\/td>\nMG-132<\/td>\n<\/tr>\n
F4005<\/td>\nPrestained Protein Marker (Triple color, EDTA free, 10-250 kDa)<\/td>\n<\/tr>\n
B1274<\/td>\nAP20187<\/td>\n<\/tr>\n
K1007<\/td>\nProtease Inhibitor Cocktail(EDTA-Free,100X in DMSO)<\/td>\n<\/tr>\n
B8226<\/td>\nInstaBlue Protein Stain Solution<\/td>\n<\/tr>\n
A3011<\/td>\nCHIR-99021 (CT99021)<\/td>\n<\/tr>\n
A3007<\/td>\nABT-263 (Navitoclax)<\/td>\n<\/tr>\n
B1524<\/td>\nErastin<\/td>\n<\/tr>\n
B6055<\/td>\nTCEP hydrochloride<\/td>\n<\/tr>\n
K1031<\/td>\nPhusion high-fidelity DNA polymerase<\/td>\n<\/tr>\n
B1387<\/td>\n(-)-Blebbistatin<\/td>\n<\/tr>\n
B4664<\/td>\nT-5224<\/td>\n<\/tr>\n
A8183<\/td>\nTrichostatin A (TSA)<\/td>\n<\/tr>\n
B3699<\/td>\nISRIB (trans-isomer)<\/td>\n<\/tr>\n
A1910<\/td>\nBromodomain Inhibitor, (+)-JQ1<\/td>\n<\/tr>\n
B1293<\/td>\nY-27632<\/td>\n<\/tr>\n
A8167<\/td>\nRapamycin (Sirolimus)<\/td>\n<\/tr>\n
A7024<\/td>\nHOAt<\/td>\n<\/tr>\n
A7025<\/td>\nHOBt (anhydrous)<\/td>\n<\/tr>\n
A8331<\/td>\nBleomycin Sulfate<\/td>\n<\/tr>\n
A4333<\/td>\nCPI-613<\/td>\n<\/tr>\n
K1070<\/td>\n2X SYBR Green qPCR Master Mix<\/td>\n<\/tr>\n
A8005<\/td>\nSulfo-NHS-SS-Biotin<\/td>\n<\/tr>\n
B4653<\/td>\nBV6<\/td>\n<\/tr>\n
B5965<\/td>\nTamoxifen<\/td>\n<\/tr>\n
A1901<\/td>\nQ-VD-OPh hydrate<\/td>\n<\/tr>\n
A8950<\/td>\nUM 171<\/td>\n<\/tr>\n
K1046<\/td>\nRNase Inhibitor, Murine<\/td>\n<\/tr>\n
A3317<\/td>\nClozapine N-oxide (CNO)<\/td>\n<\/tr>\n
A2614<\/td>\nBortezomib (PS-341)<\/td>\n<\/tr>\n
A8003<\/td>\nSulfo-NHS-LC-Biotin<\/td>\n<\/tr>\n
A4154<\/td>\nOlaparib (AZD2281, Ku-0059436)<\/td>\n<\/tr>\n
A8012<\/td>\nBiotin-XX Tyramide Reagent<\/td>\n<\/tr>\n
K1101<\/td>\nPreScission Protease (PSP)<\/td>\n<\/tr>\n
A8627<\/td>\nBafilomycin A1<\/td>\n<\/tr>\n
A8001<\/td>\nSulfo-NHS-Biotin<\/td>\n<\/tr>\n
A3017<\/td>\nDasatinib (BMS-354825)<\/td>\n<\/tr>\n
A2576<\/td>\nE-64<\/td>\n<\/tr>\n
K1051<\/td>\nCy3 TSA Fluorescence System Kit<\/td>\n<\/tr>\n
K1034<\/td>\n2X Taq PCR Master Mix (with dye)<\/td>\n<\/tr>\n
B7972<\/td>\nPseudo-UTP<\/td>\n<\/tr>\n
A8173<\/td>\nRomidepsin (FK228, depsipeptide)<\/td>\n<\/tr>\n
A4219<\/td>\nBirinapant (TL32711)<\/td>\n<\/tr>\n
A4371<\/td>\nFerrostatin-1 (Fer-1)<\/td>\n<\/tr>\n
A8200<\/td>\nDAPT (GSI-IX)<\/td>\n<\/tr>\n
A8249<\/td>\nSB 431542<\/td>\n<\/tr>\n
K1008<\/td>\nProtease Inhibitor Cocktail (EDTA-Free, 200X in DMSO)<\/td>\n<\/tr>\n
A3133<\/td>\nA 83-01<\/td>\n<\/tr>\n
A8192<\/td>\nStaurosporine<\/td>\n<\/tr>\n
B1054<\/td>\nResiquimod (R-848)<\/td>\n<\/tr>\n
A3018<\/td>\nTrametinib (GSK1120212)<\/td>\n<\/tr>\n
A8184<\/td>\nAICAR<\/td>\n<\/tr>\n
K1025<\/td>\nDirect Mouse Genotyping Kit<\/td>\n<\/tr>\n
A2606<\/td>\nEpoxomicin<\/td>\n<\/tr>\n
A6006<\/td>\nHexa His tag peptide<\/td>\n<\/tr>\n
A4393<\/td>\nPaclitaxel (Taxol)<\/td>\n<\/tr>\n
A8315<\/td>\nNU7441 (KU-57788)<\/td>\n<\/tr>\n
A4213<\/td>\nNecrostatin-1<\/td>\n<\/tr>\n
A8885<\/td>\nRo 3306<\/td>\n<\/tr>\n
L1021<\/td>\nDiscoveryProbe\u2122 FDA-approved Drug Library<\/td>\n<\/tr>\n
B1464<\/td>\nKPT-330<\/td>\n<\/tr>\n
A8815<\/td>\nSM-164<\/td>\n<\/tr>\n
B4879<\/td>\nBlasticidin S HCl<\/td>\n<\/tr>\n
A8793<\/td>\nN3-kethoxal<\/td>\n<\/tr>\n
K1047<\/td>\nHyperScribe\u2122 T7 High Yield RNA Synthesis Kit<\/td>\n<\/tr>\n
A6004<\/td>\nInfluenza Hemagglutinin (HA) Peptide<\/td>\n<\/tr>\n
B1036<\/td>\nMLN4924<\/td>\n<\/tr>\n
A8178<\/td>\nPanobinostat (LBH589)<\/td>\n<\/tr>\n
A3963<\/td>\nA-769662<\/td>\n<\/tr>\n
A3847<\/td>\nSU5416<\/td>\n<\/tr>\n
B3252<\/td>\nDorsomorphin (Compound C)<\/td>\n<\/tr>\n
B4758<\/td>\nBAPTA-AM<\/td>\n<\/tr>\n
A2513<\/td>\nGeneticin, G-418 Sulfate<\/td>\n<\/tr>\n
B6004<\/td>\nPX-478 2HCl<\/td>\n<\/tr>\n
A8955<\/td>\nZ-YVAD-FMK<\/td>\n<\/tr>\n
A8193<\/td>\nABT-737<\/td>\n<\/tr>\n
B2083<\/td>\nCaspofungin Acetate<\/td>\n<\/tr>\n
A8002<\/td>\nNHS-Biotin<\/td>\n<\/tr>\n
A8337<\/td>\nCX-5461<\/td>\n<\/tr>\n
A8312<\/td>\nTorin 1<\/td>\n<\/tr>\n
A2570<\/td>\nLeupeptin, Microbial<\/td>\n<\/tr>\n
K2170<\/td>\nAlanine Aminotransferase (ALT or SGPT) Activity Colorimetric\/Fluorometric Assay Kit<\/td>\n<\/tr>\n
A4381<\/td>\nFK866 (APO866)<\/td>\n<\/tr>\n
B2143<\/td>\nTacrolimus (FK506)<\/td>\n<\/tr>\n
A2571<\/td>\nPepstatin A<\/td>\n<\/tr>\n
k1072<\/td>\nFirst-Strand cDNA Synthesis Kit<\/td>\n<\/tr>\n
A3003<\/td>\nMDV3100 (Enzalutamide)<\/td>\n<\/tr>\n
B5997<\/td>\nDyngo-4a<\/td>\n<\/tr>\n
A3742<\/td>\nPyridostatin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n

APExBIO\u53f0\u7063\u4ee3\u7406\u5546<\/a><\/span><\/h2>\n

APExBIO\u63d0\u4f9b\u512a\u8cea\u7684\u80dc\u80bd\u548c\u751f\u7269\u5206\u6790\u8a66\u5291\uff0c\u5ee3\u6cdb\u7522\u54c1\u7dda\u5982Protease\u3001Chromatin\/Epigenetics\u8868\u89c0\u907a\u50b3\u5b78\u3001MAPK Signal\u3001DNA Damege\/DNA repair\u3001\u7d30\u80de\u51cb\u4ea1\u3001\u816b\u7624\u751f\u7269\u5b78\u3001Stem cell\u7b49\u7814\u7a76\u9818\u57df\uff0c \u9084\u63d0\u4f9b\u5b9a\u5236\u7684\u670d\u52d9\uff0c\u5305\u62ec\u591a\u80bd\u5408\u6210\uff0c\u6297\u9ad4\u7684\u751f\u7522\u548c\u6aa2\u6e2c\u7684\u767c\u5c55\u3002\u7522\u54c1\u7ddaDNA\/RNA prep kit\u3001Drug Screening panel\u3001Bioactive peptides\u3001Growth factors\u3001Biotinylation Reagents\u3001tag peptides\u3001amino Acids\u3001Growth factors\u7b49\u3002APExBIO\u7522\u54c1\u8cea\u91cf\u90fd\u4f34\u96a8\u8457\u8b49\u66f8\u7684\u5206\u6790\uff0c\u9ad8\u6548\u6db2\u76f8\u8272\u8b5c\uff0c\u8cea\u8b5c\uff0c\u548cHMNR\u6578\u64da\u3002<\/p>\n

\u00a0<\/strong><\/p>\n\n\n\n\n\n\n\n\n\n\n\n
\u54c1\u9805<\/td>\nCAS#<\/td>\n#\u8ca8\u865f<\/td>\n\u61c9\u7528<\/td>\n<\/tr>\n
Romidepsin (FK228, depsipeptide)<\/a><\/td>\n\n

CAS#128517-07-7<\/p>\n

 <\/td>\n

\u8ca8\u865fA8173<\/td>\nHDAC1\/HDAC2\uff0c\u5f37\u6548\u548c\u9078\u64c7\u6027\u6291\u5236\u5291<\/td>\n<\/tr>\n
Pirarubicin<\/a><\/td>\nCAS#72496-41-4<\/td>\n\u8ca8\u865fB2295<\/td>\n\u00a0anthracycline anti-neoplastic doxorubicin<\/td>\n<\/tr>\n
Tunicamycin<\/a><\/td>\nCAS# 15663-27-1<\/td>\n\n

\u8ca8\u865fA8321<\/p>\n

 <\/td>\n

\u9ad8\u6548\u3001\u5ee3\u8b5c\u7684\u5316\u7642\u85e5\u7269<\/td>\n<\/tr>\n
Azithromycin<\/a><\/td>\nCAS#83905-01-5<\/td>\n\u00a0\u8ca8\u865fA2213<\/td>\nHsp90 inhibitor<\/td>\n<\/tr>\n
Bleomycin Sulfate<\/a><\/td>\n\n

CAS# 9041-93-4<\/p>\n

 <\/td>\n

\u8ca8\u865fB1398<\/td>\nAntibiotic by inhibiting protein synthesis<\/td>\n<\/tr>\n
Nystatin (Fungicidin)<\/a><\/td>\nCAS#1400-61-9<\/td>\n\u8ca8\u865fB1993<\/td>\nantifungal antibiotic<\/td>\n<\/tr>\n
Rapamycin<\/a><\/td>\nCAS#53123-88-9<\/td>\n\u8ca8\u865fA8167<\/td>\nOriginal antifungal antibiotic<\/td>\n<\/tr>\n
Daptomycin<\/a><\/td>\nCAS#103060-53-3<\/td>\n\u8ca8\u865fA1206<\/td>\nCalcium-dependent antibiotic<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Catalog No.<\/td>\nName<\/td>\nCAS<\/td>\nPurity<\/td>\nShort Summary<\/td>\n<\/tr>\n
A1001<\/td>\nAdrenomedullin (1-12), human<\/td>\n<\/td>\n98.99%<\/td>\nVasodilator<\/td>\n<\/tr>\n
A1002<\/td>\nBeta-Amyloid (1-11)<\/td>\n190436-05-6<\/td>\n98.58%<\/td>\nAmyloidogenic peptide<\/td>\n<\/tr>\n
A1003<\/td>\nAmyloid \u03b2-Protein (1-15)<\/td>\n183745-81-5<\/td>\n98.58%<\/td>\nPrincipal component of amyloid<\/td>\n<\/tr>\n
A1004<\/td>\nAmyloid Precursor C-Terminal Peptide<\/td>\n<\/td>\n92.28%<\/td>\nFor beta amyloid generation<\/td>\n<\/tr>\n
A1005<\/td>\nBeta-Sheet Breaker Peptide iA\u03b25<\/td>\n182912-74-9<\/td>\n98.17%<\/td>\nPeptide which can inhibit amyloidogenesis<\/td>\n<\/tr>\n
A1006<\/td>\nAngiotensin I (human, mouse, rat)<\/td>\n484-42-4<\/td>\n98.99%<\/td>\nPrecursor of angiotensin II<\/td>\n<\/tr>\n
A1007<\/td>\nAngiotensin 1\/2 (1-9)<\/td>\n34273-12-6<\/td>\n98.77%<\/td>\nVasoconstrictor<\/td>\n<\/tr>\n
A1008<\/td>\nAnti-Inflammatory Peptide 1<\/td>\n118850-71-8<\/td>\n99.99%<\/td>\nPLA2 inhibitor<\/td>\n<\/tr>\n
A1009<\/td>\nANP (1-11), rat<\/td>\n<\/td>\n95.92%<\/td>\nVasodilator<\/td>\n<\/tr>\n
A1010<\/td>\nMyelopeptide-2 (MP-2)<\/td>\n<\/td>\n98.98%<\/td>\nPeptide used for restoring human T lymphocytes<\/td>\n<\/tr>\n
A1011<\/td>\nb-Casomorphin (1-3)<\/td>\n72122-59-9<\/td>\n99.56%<\/td>\nMilk protein casein analog, have an opioid effect<\/td>\n<\/tr>\n
A1012<\/td>\nDynorphin (2-17), amide, porcine<\/td>\n<\/td>\n99.94%<\/td>\nA modulator of pain response<\/td>\n<\/tr>\n
A1013<\/td>\nEndomorphin-1<\/td>\n189388-22-5<\/td>\n98.79%<\/td>\nAgonist of \u03bcopioid receptors,highly potent and selective<\/td>\n<\/tr>\n
A1014<\/td>\nBeta-Lipotropin (1-10), porcine<\/td>\n77875-68-4<\/td>\n99.17%<\/td>\nMorphine-like substance<\/td>\n<\/tr>\n
A1015<\/td>\nalpha-Endorphin<\/td>\n59004-96-5<\/td>\n98.00%<\/td>\nNeurotransmitters<\/td>\n<\/tr>\n
A1016<\/td>\nAc-Endothelin-1 (16-21), human<\/td>\n<\/td>\n98.49%<\/td>\nETA\/ETB agonist,vasoconstrictor<\/td>\n<\/tr>\n
A1018<\/td>\nPlatelet Membrane Glycoprotein IIB Peptide (296-306)<\/td>\n<\/td>\n98.92%<\/td>\nInhibits platelet aggregation<\/td>\n<\/tr>\n
A1019<\/td>\nGlucagon (19-29), human<\/td>\n64790-15-4<\/td>\n95.54%<\/td>\nPotent Ca2+\/Mg2+-ATPase inhibitor<\/td>\n<\/tr>\n
A1020<\/td>\nGnRH Associated Peptide (GAP) (1-13), human<\/td>\n100111-07-7<\/td>\n99.41%<\/td>\nInhibitor of prolactin secretion<\/td>\n<\/tr>\n
A1021<\/td>\nEpidermal Growth Factor Receptor Peptide (985-996)<\/td>\n96249-43-3<\/td>\n98.41%<\/td>\nEGFR Peptide (985-996)<\/td>\n<\/tr>\n
A1022<\/td>\nGTP-Binding Protein Fragment, G alpha<\/td>\n<\/td>\n74.64%<\/td>\nHydrolyzes GTP to GDP<\/td>\n<\/tr>\n
A1023<\/td>\nLaminin (925-933)<\/td>\n110590-60-8<\/td>\n99.93%<\/td>\nExtracellular matrix glycoprotein<\/td>\n<\/tr>\n
A1024<\/td>\nLEP (116-130) (mouse)<\/td>\n258276-95-8<\/td>\n98.17%<\/td>\nAn antiobesity hormone<\/td>\n<\/tr>\n
A1025<\/td>\na-MSH, amide<\/td>\n581-05-5<\/td>\n99.59%<\/td>\nMelanocyte-stimulating hormones<\/td>\n<\/tr>\n
A1026<\/td>\n\u03b2-Interleukin I (163-171), human<\/td>\n106021-96-9<\/td>\n99.58%<\/td>\nT cell activator<\/td>\n<\/tr>\n
A1027<\/td>\n\u03b2-Interleukin II (44-56)<\/td>\n<\/td>\n99.37%<\/td>\nCytokine,regulating WBC<\/td>\n<\/tr>\n
A1028<\/td>\nCadherin Peptide, avian<\/td>\n127650-08-2<\/td>\n99.90%<\/td>\nRole in cell adhesion<\/td>\n<\/tr>\n
A1029<\/td>\nFas C- Terminal Tripeptide<\/td>\n189109-90-8<\/td>\n97.61%<\/td>\nAC-SER-LEU-VAL-OH<\/td>\n<\/tr>\n
A1030<\/td>\nInterleukin II (60-70)<\/td>\n<\/td>\n99.99%<\/td>\nCytokine,regulating WBC<\/td>\n<\/tr>\n
A1031<\/td>\nMyelin Basic Protein (68-82), guinea pig<\/td>\n98474-59-0<\/td>\n99.06%<\/td>\nMyelin Basic Protein<\/td>\n<\/tr>\n
A1032<\/td>\nAdrenorphin<\/td>\n88377-68-8<\/td>\n97.00%<\/td>\nEndogenous \u03bc\/\u03ba opioid agonist,potent and selective<\/td>\n<\/tr>\n
A1033<\/td>\n[Ser25] Protein Kinase C (19-31)<\/td>\n136795-05-6<\/td>\n99.80%<\/td>\nPKC substrate<\/td>\n<\/tr>\n
A1034<\/td>\nAcetyl Angiotensinogen (1-14), porcine<\/td>\n66641-26-7<\/td>\n99.81%<\/td>\nAngiotensinogen precursor<\/td>\n<\/tr>\n
A1035<\/td>\nPapain Inhibitor<\/td>\n70195-20-9<\/td>\n97.15%<\/td>\nInhibitor of peptidase activity of Papain<\/td>\n<\/tr>\n
A1036<\/td>\nThrombin Receptor Activator for Peptide 5 (TRAP-5)<\/td>\n141685-53-2<\/td>\n98.07%<\/td>\nThrombin Receptor Activator for Peptide 5<\/td>\n<\/tr>\n
A1037<\/td>\nTRH Precursor Peptide<\/td>\n<\/td>\n98.91%<\/td>\nThyrotropin Releasing Hormone Precursor Peptide<\/td>\n<\/tr>\n
A1040<\/td>\nMyelin Basic Protein (87-99)<\/td>\n118506-26-6<\/td>\n99.85%<\/td>\nEncephalitogenic peptide<\/td>\n<\/tr>\n
A1041<\/td>\nAngiotensin (1-7)<\/td>\n51833-78-4<\/td>\n99.70%<\/td>\nVasoconstriction peptide hormone<\/td>\n<\/tr>\n
A1043<\/td>\nAngiotensin III (human, mouse)<\/td>\n13602-53-4<\/td>\n98.97%<\/td>\nAldosterone stimulator<\/td>\n<\/tr>\n
A1044<\/td>\nGap 26<\/td>\n197250-15-0<\/td>\n99.56%<\/td>\nGap junction blocker peptide, mapping to connexin 43 residue 63-75<\/td>\n<\/tr>\n
A1045<\/td>\nGap 27<\/td>\n198284-64-9<\/td>\n97.64%<\/td>\nSelective gap junction blocker<\/td>\n<\/tr>\n
A1046<\/td>\nDynamin inhibitory peptide<\/td>\n251634-21-6<\/td>\n99.53%<\/td>\nPeptide inhibitor of GTPase dynamin<\/td>\n<\/tr>\n
A1047<\/td>\nAngiotensin 1\/2 (1-5)<\/td>\n58442-64-1<\/td>\n99.65%<\/td>\nVasoconstrictor<\/td>\n<\/tr>\n
A1048<\/td>\nAngiotensin 1\/2 (1-6)<\/td>\n47896-63-9<\/td>\n99.85%<\/td>\nVasoconstrictor<\/td>\n<\/tr>\n
A1049<\/td>\nAngiotensin 1\/2 (5-7)<\/td>\n<\/td>\n98.36%<\/td>\nVasoconstrictor<\/td>\n<\/tr>\n
A1050<\/td>\nAngiotensin 1\/2 (2-7)<\/td>\n<\/td>\n99.80%<\/td>\nVasoconstrictor<\/td>\n<\/tr>\n
A1051<\/td>\nalpha-1 antitrypsin fragment<\/td>\n<\/td>\n99.10%<\/td>\nProtease inhibitor<\/td>\n<\/tr>\n
A1052<\/td>\nalpha-1 antitrypsin fragment 235-243 [Homo sapiens]\/[Papio hamadryas]\/[Cercopithecus aethiops]<\/td>\n98.00%<\/td>\nProtease inhibitor<\/td>\n<\/tr>\n
A1053<\/td>\namyloid A protein fragment [Homo sapiens]<\/td>\n<\/td>\n99.77%<\/td>\nApolipoproteins related to HDL in plasma<\/td>\n<\/tr>\n
A1056<\/td>\nAngiotensin 1\/2 + A (2 – 8)<\/td>\n51833-76-2<\/td>\n99.56%<\/td>\nVasoconstrictor<\/td>\n<\/tr>\n
A1057<\/td>\ncoagulation factor II (thrombin) B chain fragment [Homo sapiens]<\/td>\n99.68%<\/td>\nTrypsin-like serine protease<\/td>\n<\/tr>\n
A1058<\/td>\nProthrombin (474-477) [Mus musculus]<\/td>\n<\/td>\n99.61%<\/td>\nRole in coagulation cascade<\/td>\n<\/tr>\n
A1061<\/td>\nCytochrome c – pigeon (88-104)<\/td>\n86579-06-8<\/td>\n98.58%<\/td>\nTriggers T Cell response<\/td>\n<\/tr>\n
A1062<\/td>\nCytochrome c fragment (93-108)<\/td>\n<\/td>\n99.20%<\/td>\nInitiates apoptosis<\/td>\n<\/tr>\n
A1063<\/td>\nCytochrome P450 CYP1B1 (190-198) [Homo sapiens]<\/td>\n<\/td>\n98.32%<\/td>\nSequence: H2N-FLDPRPLTV-OH<\/td>\n<\/tr>\n
A1066<\/td>\nerbB-2<\/td>\n<\/td>\n99.72%<\/td>\nTyrosine kinase (TK) receptor<\/td>\n<\/tr>\n
A1067<\/td>\neukaryotic translation elongation factor 1 alpha 1 (EEF1A1) (387-394) [Multiple species]<\/td>\n98.20%<\/td>\nElongation factor-1 subunit<\/td>\n<\/tr>\n
A1068<\/td>\neukaryotic translation initiation factor 3<\/td>\n<\/td>\n98.44%<\/td>\nEukaryotic translation initiator<\/td>\n<\/tr>\n
A1069<\/td>\nferritin heavy chain fragment [Multiple species]<\/td>\n<\/td>\n99.67%<\/td>\nFerritin heavy chain fragment<\/td>\n<\/tr>\n
A1070<\/td>\nIgG light chain variable region [Homo sapiens]\/IgM\/kappa antibody [Mus musculus]<\/td>\n99.79%<\/td>\nIgG light chain region<\/td>\n<\/tr>\n
A1071<\/td>\nimmunoglobulin light chain variable region fragment [Homo sapiens]<\/td>\n99.82%<\/td>\nImmunoglobulin light chain fragment<\/td>\n<\/tr>\n
A1072<\/td>\nimmunoglobulin light chain variable region fragment [Homo sapiens]\/[Mus musculus]<\/td>\n97.50%<\/td>\nImmunoglobulin light chain fragment<\/td>\n<\/tr>\n
A1073<\/td>\nImmunoglobulin M heavy chain (IGHM) fragment [Homo sapiens]<\/td>\n99.36%<\/td>\nImmunoglobulin M heavy chain<\/td>\n<\/tr>\n
A1075<\/td>\nInfluenza A virus fragment<\/td>\n<\/td>\n97.61%<\/td>\nLeu-Lys-Phe-Ala-Phe-Ser-Met-Met<\/td>\n<\/tr>\n
A1077<\/td>\nLamin fragment<\/td>\n<\/td>\n99.57%<\/td>\nLys-Ala-Gly-Gln-Val-Val-Thr-Ile-Trp<\/td>\n<\/tr>\n
A1078<\/td>\nLarge T antigen – rhesus polyomavirus 560-568<\/td>\n<\/td>\n99.08%<\/td>\nLarge T antigen<\/td>\n<\/tr>\n
A1079<\/td>\nMAP kinase fragment [Multiple species]<\/td>\n<\/td>\n97.00%<\/td>\nLys-Tyr-Ile-His-Ser-Ala-Asn-Val-Leu<\/td>\n<\/tr>\n
A1080<\/td>\nmatrix protein (3-15) [Zaire ebolavirus]<\/td>\n<\/td>\n98.14%<\/td>\nViral envelope associated protein peptide<\/td>\n<\/tr>\n
A1081<\/td>\nMHC class II antigen (45-57) [Homo sapiens]<\/td>\n<\/td>\n83.75%<\/td>\nMajor histocompatibility complex<\/td>\n<\/tr>\n
A1082<\/td>\novalbumin (324-338) [Gallus gallus]\/[Coturnix coturnix]<\/td>\n<\/td>\n98.23%<\/td>\nTriggers immuno response<\/td>\n<\/tr>\n
A1083<\/td>\np53 tumor suppressor fragment<\/td>\n<\/td>\n99.00%<\/td>\nRegulates cell cycle<\/td>\n<\/tr>\n
A1084<\/td>\nparathyroid hormone (7-34) [Homo sapiens]\/[Macaca fascicularis]<\/td>\n99.71%<\/td>\nEnhancer of blood calcium level<\/td>\n<\/tr>\n
A1085<\/td>\nprostate apoptosis response protein PAR-4 (2-7) [Homo sapiens]<\/td>\n<\/td>\n99.46%<\/td>\nTranscriptional repressor<\/td>\n<\/tr>\n
A1086<\/td>\nRac GTPase fragment<\/td>\n<\/td>\n99.65%<\/td>\nFragment of small signaling G proteins<\/td>\n<\/tr>\n
A1087<\/td>\nRhodopsin peptide<\/td>\n<\/td>\n99.88%<\/td>\nPigment in retina photoreceptor cell;GPCR<\/td>\n<\/tr>\n
A1088<\/td>\nRibosomal protein L3 peptide (202-222) amide<\/td>\n<\/td>\n99.76%<\/td>\nHIV-1 TAR RNA-binding protein<\/td>\n<\/tr>\n
A1090<\/td>\nsignal transducer and activator of transcription 6 fragment<\/td>\n<\/td>\n99.79%<\/td>\nSTAT6 transcription factor<\/td>\n<\/tr>\n
A1092<\/td>\nsurvivin (baculoviral IAP repeat-containing protein 5) (21-28)<\/td>\n<\/td>\n98.07%<\/td>\nCancer Biology Peptides<\/td>\n<\/tr>\n
A1093<\/td>\ntransferrin fragment<\/td>\n<\/td>\n99.69%<\/td>\nTransferrin fragment<\/td>\n<\/tr>\n
A1094<\/td>\ntumor protein p53 binding protein fragment [Homo sapiens]\/[Mus musculus]<\/td>\n99.06%<\/td>\nP53 binding protein fragment<\/td>\n<\/tr>\n
A1096<\/td>\ntype II collagen fragment<\/td>\n<\/td>\n99.56%<\/td>\nSpecific for cartilaginous tissues<\/td>\n<\/tr>\n
A1097<\/td>\nubiquitin specific protease 3 fragment<\/td>\n<\/td>\n96.99%<\/td>\nDeubiquitinates uH2A\/uH2B<\/td>\n<\/tr>\n
A1098<\/td>\nvitamin D binding protein precrusor (208-218) [Homo sapiens]\/[Oryctolagus cuniculus]<\/td>\n99.83%<\/td>\nvitamin D binding protein precrusor<\/td>\n<\/tr>\n
A1099<\/td>\nvitamin D binding protein precursor (353-363) [Homo sapiens]<\/td>\n<\/td>\n99.52%<\/td>\nHighly polymorphic serum glycoprotein<\/td>\n<\/tr>\n
A1105<\/td>\nBNP (1-32), human<\/td>\n114471-18-0<\/td>\n98.00%<\/td>\nBrain natriuretic peptide<\/td>\n<\/tr>\n
A1107<\/td>\nCdk2\/Cyclin Inhibitory Peptide I<\/td>\n<\/td>\n99.88%<\/td>\nCell division protein kinase 2<\/td>\n<\/tr>\n
A1109<\/td>\nEndostatin (84-114)-NH2 (JKC367)<\/td>\n<\/td>\n99.66%<\/td>\nAngiogenesis inhibitor<\/td>\n<\/tr>\n
A1111<\/td>\nEndothelin-1 (1-15), amide, human<\/td>\n<\/td>\n98.00%<\/td>\nVasoconstrictor agent<\/td>\n<\/tr>\n
A1112<\/td>\nNitric Oxide Synthase (599-613) Blocking Peptide, Bovine Endothelial Cell<\/td>\n99.74%<\/td>\nBlocker of NO production<\/td>\n<\/tr>\n
A1114<\/td>\nParathyroid Hormone (1-34), bovine<\/td>\n12583-68-5<\/td>\n99.84%<\/td>\nEnhancer of blood calcium level<\/td>\n<\/tr>\n
A1115<\/td>\nPeptide YY(3-36), PYY, human<\/td>\n123583-37-9<\/td>\n96.92%<\/td>\nY2R agonist<\/td>\n<\/tr>\n
A1117<\/td>\nPKA inhibitor fragment (6-22) amide<\/td>\n121932-06-7<\/td>\n98.62%<\/td>\nPKA inhibitor<\/td>\n<\/tr>\n
A1118<\/td>\nS6 Kinase Substrate Peptide 32<\/td>\n<\/td>\n98.28%<\/td>\nMeasures the activity of kinases that phosphorylate ribosomal protein S6.<\/td>\n<\/tr>\n
A1121<\/td>\nMelanocyte stimulating hormone release inhibiting factor<\/td>\n2002-44-0<\/td>\n98.00%<\/td>\nMSH release-inhibiting factor<\/td>\n<\/tr>\n
A1123<\/td>\nAmyloid Beta-Peptide (12-28) (human)<\/td>\n107015-83-8<\/td>\n99.46%<\/td>\nsequence H2N-VHHQKLVFFAEDVGSNK-OH<\/td>\n<\/tr>\n
A1124<\/td>\nAmyloid Beta-Peptide (1-40) (human)<\/td>\n131438-79-4<\/td>\n98.43%<\/td>\nAmyloid precursor protein<\/td>\n<\/tr>\n
A1129<\/td>\nParathyroid hormone (1-34) (human)<\/td>\n52232-67-4<\/td>\n99.82%<\/td>\nIncreases blood calcium level<\/td>\n<\/tr>\n
A1131<\/td>\nCOG 133<\/td>\n514200-66-9<\/td>\n99.03%<\/td>\nApoE mimetic peptide<\/td>\n<\/tr>\n
A1132<\/td>\n\u03b2-Pompilidotoxin<\/td>\n216064-36-7<\/td>\n99.84%<\/td>\nSlows Na+ channel inactivation<\/td>\n<\/tr>\n
A1133<\/td>\nEpidermal growth factor receptor (994-1002) acetyl\/amide<\/td>\n<\/td>\n98.50%<\/td>\nEGF-family receptor<\/td>\n<\/tr>\n
A1134<\/td>\nAgouti-related Protein (AGRP) (25-82), human<\/td>\n<\/td>\n99.67%<\/td>\nAgouti-related peptide(25-82)<\/td>\n<\/tr>\n
A1136<\/td>\nFusion glycoprotein (92-106) [Human respiratory syncytial virus]<\/td>\n98.42%<\/td>\nglycoprotein<\/td>\n<\/tr>\n
A1138<\/td>\nGlycoprotein B (485-492)<\/td>\n<\/td>\n99.61%<\/td>\nInvovled in HSV viral cell entry<\/td>\n<\/tr>\n
A1140<\/td>\nHBcAg [Hepatitis B virus] (18-27)<\/td>\n<\/td>\n99.74%<\/td>\nIndicator of active viral replication<\/td>\n<\/tr>\n
A1141<\/td>\nhemagglutinin (332-340) [Influenza A virus]<\/td>\n<\/td>\n98.84%<\/td>\nPartial antigenic glycoprotein<\/td>\n<\/tr>\n
A1142<\/td>\nhemagglutinin precursor (114-122) amide [Influenza A virus]<\/td>\n<\/td>\n99.70%<\/td>\nPartial antigenic glycoprotein<\/td>\n<\/tr>\n
A1143<\/td>\nheparin cofactor II precursor (SERPIND1) fragment [Homo sapiens]<\/td>\n98.14%<\/td>\nThrombin inhibitor<\/td>\n<\/tr>\n
A1144<\/td>\nheparin cofactor II precursor fragment [Homo sapiens]<\/td>\n<\/td>\n99.72%<\/td>\nThrombin inhibitor<\/td>\n<\/tr>\n
A1146<\/td>\nHistone-H2A-(107-122)-Ac-OH<\/td>\n<\/td>\n97.81%<\/td>\nHistone-H2A peptide<\/td>\n<\/tr>\n
A1147<\/td>\nLuteinizing hormone releasing hormone human acetate salt (LHRH)<\/td>\n33515-09-2<\/td>\n98.34%<\/td>\nacitivator of MMP-2 and MMP-9, selective<\/td>\n<\/tr>\n
A1149<\/td>\nYAP-TEAD Inhibitor 1 (Peptide 17)<\/td>\n<\/td>\n99.56%<\/td>\n<\/td>\n<\/tr>\n
A1169<\/td>\n10058-F4<\/td>\n403811-55-2<\/td>\n98.03%<\/td>\nC-Myc-Max dimerization inhibitor<\/td>\n<\/tr>\n
A1173<\/td>\nAG-18<\/td>\n118409-57-7<\/td>\n99.68%<\/td>\nEGFR\/PDGFR inhibitor<\/td>\n<\/tr>\n
A1174<\/td>\nAMG-517<\/td>\n659730-32-2<\/td>\n96.97%<\/td>\nTRPV1 antagonist,potent and highly selective<\/td>\n<\/tr>\n
A1185<\/td>\nBMS-754807<\/td>\n1001350-96-4<\/td>\n99.53%<\/td>\nIGF-1R\/InsR inhibitor,potent and selective<\/td>\n<\/tr>\n
A1186<\/td>\nAMG-208<\/td>\n1002304-34-8<\/td>\n98.00%<\/td>\nC-Met inhibitor,potent and highly selective<\/td>\n<\/tr>\n
A1196<\/td>\nSGX-523<\/td>\n1022150-57-7<\/td>\n99.73%<\/td>\nMET inibitor, highly selective, ATP-competitive<\/td>\n<\/tr>\n
A1198<\/td>\nLevetiracetam<\/td>\n102767-28-2<\/td>\n98.00%<\/td>\nAntiepileptic drug<\/td>\n<\/tr>\n
A1206<\/td>\nDaptomycin<\/td>\n103060-53-3<\/td>\n98.77%<\/td>\nCalcium-dependent antibiotic<\/td>\n<\/tr>\n
A1229<\/td>\nLansoprazole<\/td>\n103577-45-3<\/td>\n98.00%<\/td>\nH+,K+-ATPase inhibitor<\/td>\n<\/tr>\n
A1266<\/td>\nWYE-354<\/td>\n1062169-56-5<\/td>\n99.39%<\/td>\nMTOR inhibitor,potent,ATP-competitive and cell-permeable<\/td>\n<\/tr>\n
A1267<\/td>\nAdapalene<\/td>\n106685-40-9<\/td>\n99.91%<\/td>\nRAR\u03b2 and RAR\u03b3 agonist<\/td>\n<\/tr>\n
A1295<\/td>\nGranisetron HCl<\/td>\n107007-99-8<\/td>\n99.85%<\/td>\n5-HT3 receptor antagonist<\/td>\n<\/tr>\n
A1296<\/td>\nExemestane<\/td>\n107868-30-4<\/td>\n98.00%<\/td>\nSteroidal aromatase inhibitor,selective and irreversible<\/td>\n<\/tr>\n
A1302<\/td>\nGSK1904529A<\/td>\n1089283-49-7<\/td>\n98.55%<\/td>\nSelective IGF-1R\/IR inhibitor<\/td>\n<\/tr>\n
A1307<\/td>\nLetrozole<\/td>\n112809-51-5<\/td>\n99.90%<\/td>\nNon-steroidal aromatase inhibitor<\/td>\n<\/tr>\n
A1313<\/td>\nGatifloxacin<\/td>\n112811-59-3<\/td>\n99.70%<\/td>\nFluoroquinolone antibiotic,inhibits bacterial TOPO II<\/td>\n<\/tr>\n
A1334<\/td>\nMosapride Citrate<\/td>\n112885-42-4<\/td>\n99.90%<\/td>\n5-HT receptor agonist<\/td>\n<\/tr>\n
A1337<\/td>\nU0126-EtOH<\/td>\n1173097-76-1<\/td>\n99.34%<\/td>\nMEK1\/2 inhibitor<\/td>\n<\/tr>\n
A1352<\/td>\nZoledronic Acid<\/td>\n118072-93-8<\/td>\n98.00%<\/td>\nPotent nitrogen-containing bisphosphonates<\/td>\n<\/tr>\n
A1366<\/td>\nRocuronium Bromide<\/td>\n119302-91-9<\/td>\n98.00%<\/td>\nTGF-\u03b2R I kinase inhibitor<\/td>\n<\/tr>\n
A1367<\/td>\nAP26113<\/td>\n1197958-12-5<\/td>\n98.00%<\/td>\nAnaplastic lymphoma kinase (ALK) inhibitor<\/td>\n<\/tr>\n
A1372<\/td>\nAZD3514<\/td>\n1240299-33-5<\/td>\n98.00%<\/td>\nAndrogen receptor downregulator<\/td>\n<\/tr>\n
A1373<\/td>\nBiapenem<\/td>\n120410-24-4<\/td>\n98.00%<\/td>\nHighly broad spectrum antibiotic agent<\/td>\n<\/tr>\n
A1379<\/td>\nNelarabine<\/td>\n121032-29-9<\/td>\n98.44%<\/td>\nProdrug of ara-G for T-LBL\/T-ALL<\/td>\n<\/tr>\n
A1379<\/td>\nNelarabine<\/td>\n121032-29-9<\/td>\n98.44%<\/td>\nProdrug of ara-G for T-LBL\/T-ALL<\/td>\n<\/tr>\n
A1379<\/td>\nNelarabine<\/td>\n121032-29-9<\/td>\n98.44%<\/td>\nProdrug of ara-G for T-LBL\/T-ALL<\/td>\n<\/tr>\n
A1379<\/td>\nNelarabine<\/td>\n121032-29-9<\/td>\n98.44%<\/td>\nProdrug of ara-G for T-LBL\/T-ALL<\/td>\n<\/tr>\n
A1387<\/td>\nAZD5363<\/td>\n1143532-39-1<\/td>\n99.94%<\/td>\nAKT inhibitor,pyrrolopyrimidine derived<\/td>\n<\/tr>\n
A1389<\/td>\nWZ4002<\/td>\n1213269-23-8<\/td>\n98.89%<\/td>\nMutant-selective EGFR inhibitor(L858R,T790M), irreversible and potent<\/td>\n<\/tr>\n
A1393<\/td>\nWZ8040<\/td>\n1214265-57-2<\/td>\n98.36%<\/td>\nEGFR T790M inhibitor,irreversible amd potent<\/td>\n<\/tr>\n
A1402<\/td>\nGemcitabine HCl<\/td>\n122111-03-9<\/td>\n99.92%<\/td>\nInhibits DNA synthesis,deoxycytidine analog<\/td>\n<\/tr>\n
A1404<\/td>\nRigosertib sodium salt<\/td>\n1225497-78-8<\/td>\n98.79%<\/td>\nPlk1 inhibitor<\/td>\n<\/tr>\n
A1412<\/td>\nClofarabine<\/td>\n123318-82-1<\/td>\n99.41%<\/td>\nAntimetabolite,inhibit DNA polymerase and ribonucleotide reductase<\/td>\n<\/tr>\n
A1413<\/td>\nCEP-32496<\/td>\n1188910-76-0<\/td>\n98.27%<\/td>\nBRAF(V600E)inhibitor,highly potent<\/td>\n<\/tr>\n
A1425<\/td>\nLosartan Potassium (DuP 753)<\/td>\n124750-99-8<\/td>\n99.87%<\/td>\nAngiotensin AT1 receptor antagonist<\/td>\n<\/tr>\n
A1428<\/td>\nFulvestrant (ICI 182,780)<\/td>\n129453-61-8<\/td>\n99.18%<\/td>\nEstrogen receptor antagonist, high affinity<\/td>\n<\/tr>\n
A1435<\/td>\nCP-945598 HCl<\/td>\n686347-12-6<\/td>\n98.00%<\/td>\nCB1 antagonist,selective and high affinity<\/td>\n<\/tr>\n
A1447<\/td>\nCilnidipine<\/td>\n132203-70-4<\/td>\n99.94%<\/td>\nBlocker of Dual L- and N-type calcium channel<\/td>\n<\/tr>\n
A1450<\/td>\nLidocaine<\/td>\n137-58-6<\/td>\n99.92%<\/td>\nAnasthetic and class Ib antiarrhythmic agent<\/td>\n<\/tr>\n
A1493<\/td>\nABT-751 (E7010)<\/td>\n141430-65-1<\/td>\n99.38%<\/td>\nInhibitor of microtubule polymerization,antimitotic<\/td>\n<\/tr>\n
A1500<\/td>\n7-Methoxycoumarin-4-acetyl-P-L-G-L-\u03b2-(2,4-dinitrophenylamino)A-R amide<\/td>\n140430-53-1<\/td>\n99.93%<\/td>\nSubstrate of matrix metalloproteinases assay<\/td>\n<\/tr>\n
A1501<\/td>\nMca-Pro-Leu-NH2<\/td>\n<\/td>\n98.00%<\/td>\nSubstrate of matrix metalloproteinases assay<\/td>\n<\/tr>\n
A1602<\/td>\nDexrazoxane HCl (ICRF-187, ADR-529)<\/td>\n149003-01-0<\/td>\n99.85%<\/td>\nTopoisomerase II inhibitor,intracellular ion chelator,cardioprotective agent<\/td>\n<\/tr>\n
A1605<\/td>\nDynasore<\/td>\n304448-55-3<\/td>\n98.00%<\/td>\nDynamin and GTPase inhibitor<\/td>\n<\/tr>\n
A1606<\/td>\nL-a-Hydroxyglutaric acid disodium salt<\/td>\n63512-50-5<\/td>\n95.00%<\/td>\nsalt form of L-\u03b1-Hydroxyglutaric acid<\/td>\n<\/tr>\n
A1615<\/td>\nGANT61<\/td>\n500579-04-4<\/td>\n99.50%<\/td>\nGLI antagonist<\/td>\n<\/tr>\n
A1623<\/td>\nEpothilone A<\/td>\n152044-53-6<\/td>\n98.00%<\/td>\nMicrotubule stabilizing macrolide<\/td>\n<\/tr>\n
A1624<\/td>\nZaragozic Acid A<\/td>\n142561-96-4<\/td>\n98.00%<\/td>\nrat liver squalene synthase inhibitor<\/td>\n<\/tr>\n
A1630<\/td>\nEpothilone B (EPO906, Patupilone)<\/td>\n152044-54-7<\/td>\n99.72%<\/td>\nMicrotubule stabilizing macrolide<\/td>\n<\/tr>\n
A1632<\/td>\nSB202190 (FHPI)<\/td>\n152121-30-7<\/td>\n99.84%<\/td>\nP38 MAPK inhibitor<\/td>\n<\/tr>\n
A1655<\/td>\nGW2580<\/td>\n870483-87-7<\/td>\n99.69%<\/td>\nCFMS kinase\/CSF-1R inhibitor,selective and ATP-competitive<\/td>\n<\/tr>\n
A1659<\/td>\nDutasteride<\/td>\n164656-23-9<\/td>\n99.46%<\/td>\n5-alpha-reductase inhibitor<\/td>\n<\/tr>\n
A1663<\/td>\nPD98059<\/td>\n167869-21-8<\/td>\n99.25%<\/td>\nMEK inhibitor,selective and reversible<\/td>\n<\/tr>\n
A1664<\/td>\nCelecoxib<\/td>\n169590-42-5<\/td>\n99.71%<\/td>\nSelective cyclooxygenase-2 (COX-2) inhibitor<\/td>\n<\/tr>\n
A1670<\/td>\nEnzastaurin (LY317615)<\/td>\n170364-57-5<\/td>\n98.94%<\/td>\nPKC beta inhibitor,potent and selective<\/td>\n<\/tr>\n
A1684<\/td>\nAprepitant<\/td>\n170729-80-3<\/td>\n98.62%<\/td>\nSubstance P (SP) inhibitor<\/td>\n<\/tr>\n
A1709<\/td>\nGW9508<\/td>\n885101-89-3<\/td>\n99.93%<\/td>\nFFA1\/GPR40 agonist,potent and selective<\/td>\n<\/tr>\n
A1718<\/td>\nPosaconazole<\/td>\n171228-49-2<\/td>\n99.47%<\/td>\nSterol C14\u0251 demethylase inhibitor<\/td>\n<\/tr>\n
A1720<\/td>\nDuvelisib (IPI-145, INK1197)<\/td>\n1201438-56-3<\/td>\n99.55%<\/td>\nPI3K-\u03b4\/PI3K-\u03b3 inhibitor<\/td>\n<\/tr>\n
A1723<\/td>\nRoscovitine (Seliciclib,CYC202)<\/td>\n186692-46-6<\/td>\n99.10%<\/td>\nCDK inhibitor,potent and selective<\/td>\n<\/tr>\n
A1736<\/td>\nPA-824<\/td>\n187235-37-6<\/td>\n99.62%<\/td>\nAnti-tuberculosis drug<\/td>\n<\/tr>\n
A1745<\/td>\nGalanthamine HBr<\/td>\n1953-04-4<\/td>\n98.81%<\/td>\nAcetylcholinesterase inhibitor<\/td>\n<\/tr>\n
A1748<\/td>\nRamelteon<\/td>\n196597-26-9<\/td>\n99.89%<\/td>\nAgonist of melatonin receptor(M1-M2),highly selective<\/td>\n<\/tr>\n
A1755<\/td>\nTenofovir Disoproxil Fumarate<\/td>\n202138-50-9<\/td>\n98.61%<\/td>\nAntiretroviral agent( HIV-1 RT inhibitor)<\/td>\n<\/tr>\n
A1765<\/td>\nVincristine sulfate<\/td>\n2068-78-2<\/td>\n98.64%<\/td>\nMicrotubule disrupter,antitumor agent<\/td>\n<\/tr>\n
A1767<\/td>\nEntecavir Hydrate<\/td>\n209216-23-9<\/td>\n99.67%<\/td>\nAntiviral drug used in hepatitis B infection<\/td>\n<\/tr>\n
A1769<\/td>\nKU-0060648<\/td>\n881375-00-4<\/td>\n98.00%<\/td>\nDual DNA-PK\/PI3-K inhibitor, ATP-competitive<\/td>\n<\/tr>\n
A1778<\/td>\nVatalanib (PTK787) 2HCl<\/td>\n212141-51-0<\/td>\n99.95%<\/td>\nTyrosine kinase receptor inhibitor<\/td>\n<\/tr>\n
A1792<\/td>\nPD184352 (CI-1040)<\/td>\n212631-79-3<\/td>\n99.41%<\/td>\nSelective MEK inhibitor<\/td>\n<\/tr>\n
A1794<\/td>\nLY2835219<\/td>\n1231930-82-7<\/td>\n98.48%<\/td>\nCDK4\/6 inhibitor,potent and selective<\/td>\n<\/tr>\n
A1796<\/td>\nMianserin HCl<\/td>\n21535-47-7<\/td>\n99.42%<\/td>\n5-HT2 receptor antagonist<\/td>\n<\/tr>\n
A1821<\/td>\nKi8751<\/td>\n228559-41-9<\/td>\n99.43%<\/td>\nVEGFR-2 inhibitor,potent and selective<\/td>\n<\/tr>\n
A1832<\/td>\nDoxorubicin (Adriamycin) HCl<\/td>\n25316-40-9<\/td>\n99.64%<\/td>\nAntitumour antibiotic,inhibits TOPO II.<\/td>\n<\/tr>\n
A1835<\/td>\nPelitinib (EKB-569)<\/td>\n257933-82-7<\/td>\n98.49%<\/td>\nEGFR inhibitor,potent and irreversible<\/td>\n<\/tr>\n
A1845<\/td>\nCanertinib (CI-1033)<\/td>\n267243-28-7<\/td>\n99.52%<\/td>\nHER family tyrosine kinase inhibitor<\/td>\n<\/tr>\n
A1855<\/td>\nBumetanide<\/td>\n28395-03-1<\/td>\n98.77%<\/td>\nNKCC cotransporter inhibitor<\/td>\n<\/tr>\n
A1882<\/td>\nCediranib (AZD217)<\/td>\n288383-20-0<\/td>\n99.82%<\/td>\nVEGFR inhibitor receptor,highly potent<\/td>\n<\/tr>\n
A1888<\/td>\nTRAM-34<\/td>\n289905-88-0<\/td>\n98.00%<\/td>\nKCa3.1 blocker,potent and highly selective<\/td>\n<\/tr>\n
A1894<\/td>\nSL-327<\/td>\n305350-87-2<\/td>\n99.80%<\/td>\nSelective MEK1\/2 inhibitor<\/td>\n<\/tr>\n
A1900<\/td>\nPSI<\/td>\n158442-41-2<\/td>\n97.64%<\/td>\nProteasome inhibitor<\/td>\n<\/tr>\n
A1901<\/td>\nQ-VD-OPh hydrate<\/td>\n1135695-98-5<\/td>\n98.32%<\/td>\nCell-permeable, irreversible pan-caspase inhibitor<\/td>\n<\/tr>\n
A1902<\/td>\nZ-VAD-FMK<\/td>\n187389-52-2<\/td>\n98.60%<\/td>\nCell-permeable, irreversible pan-caspase inhibitor<\/td>\n<\/tr>\n
A1903<\/td>\nE 64d<\/td>\n88321-09-9<\/td>\n98.14%<\/td>\nCysteine protease inhibitor<\/td>\n<\/tr>\n
A1904<\/td>\nBoc-D-FMK<\/td>\n187389-53-3,634911-80-1<\/td>\n98.00%<\/td>\nPan-caspase inhibitor<\/td>\n<\/tr>\n
A1905<\/td>\n3-Deazaneplanocin,DZNep<\/td>\n102052-95-9<\/td>\n98.00%<\/td>\nS-adenosylhomocysteine and EZH2 inhibitor<\/td>\n<\/tr>\n
A1906<\/td>\nDecitabine (NSC127716, 5AZA-CdR)<\/td>\n2353-33-5<\/td>\n99.77%<\/td>\nDeoxycytidine analog and cellular diifferentiation inducer<\/td>\n<\/tr>\n
A1907<\/td>\n5-Azacytidine<\/td>\n320-67-2<\/td>\n98.00%<\/td>\nDNA methyltransferase inhibitor.<\/td>\n<\/tr>\n
A1908<\/td>\nAMI-1<\/td>\n20324-87-2<\/td>\n99.49%<\/td>\nPRMT1 inhibitor<\/td>\n<\/tr>\n
A1909<\/td>\nBIX 01294<\/td>\n935693-62-2<\/td>\n98.38%<\/td>\nG9a and GLP inhibitor<\/td>\n<\/tr>\n
A1910<\/td>\nBromodomain Inhibitor, (+)-JQ1<\/td>\n1268524-70-4<\/td>\n98.98%<\/td>\nBET bromodomain inhibitor<\/td>\n<\/tr>\n
A1912<\/td>\nLomeguatrib<\/td>\n192441-08-0<\/td>\n99.55%<\/td>\nMGMT inhibitor<\/td>\n<\/tr>\n
A1913<\/td>\nRG 108<\/td>\n48208-26-0<\/td>\n99.86%<\/td>\nDNA methyltransferase inhibitor<\/td>\n<\/tr>\n
A1914<\/td>\nUNC0638<\/td>\n1255580-76-7<\/td>\n98.66%<\/td>\nG9a\/GLP HMTase inhibitor, potent and selective<\/td>\n<\/tr>\n
A1915<\/td>\nZebularine<\/td>\n3690-10-6<\/td>\n99.18%<\/td>\nDNA methylation inhibitor<\/td>\n<\/tr>\n
A1920<\/td>\nZ-DEVD-FMK<\/td>\n210344-95-9<\/td>\n98.00%<\/td>\nCaspase-3 inhibitor<\/td>\n<\/tr>\n
A1921<\/td>\nZ-DQMD-FMK<\/td>\n767287-99-0<\/td>\n98.00%<\/td>\nCaspase-3 inhibitor,cell-permeable<\/td>\n<\/tr>\n
A1922<\/td>\nZ-VDVAD-FMK<\/td>\n210344-92-6<\/td>\n98.00%<\/td>\nCaspase-2 inhibitor<\/td>\n<\/tr>\n
A1923<\/td>\nZ-VEID-FMK<\/td>\n<\/td>\n98.41%<\/td>\nCaspase-6 inhibitor<\/td>\n<\/tr>\n
A1924<\/td>\nZ-WEHD-FMK<\/td>\n210345-00-9<\/td>\n98.00%<\/td>\nCaspase 5 inhibitor,potent,cell-permeable and irreversible<\/td>\n<\/tr>\n
A1925<\/td>\nCaspase-3\/7 Inhibitor I<\/td>\n220509-74-0<\/td>\n99.31%<\/td>\nCaspase-3\/7 inhibitor<\/td>\n<\/tr>\n
A1926<\/td>\nCA 074<\/td>\n134448-10-5<\/td>\n98.07%<\/td>\nCathepsin B inhibitor<\/td>\n<\/tr>\n
A1930<\/td>\nApoptosis Inhibitor<\/td>\n54135-60-3<\/td>\n99.70%<\/td>\nAssociate with caspase-3 inhibition<\/td>\n<\/tr>\n
A1931<\/td>\nPyronaridine Tetraphosphate<\/td>\n76748-86-2<\/td>\n99.47%<\/td>\nAntimalarial agent<\/td>\n<\/tr>\n
A1932<\/td>\n(-)-Huperzine A<\/td>\n102518-79-6<\/td>\n99.63%<\/td>\nNMDA receptor antagonist\/AChE inhibitor<\/td>\n<\/tr>\n
A1933<\/td>\nCarfilzomib (PR-171)<\/td>\n868540-17-4<\/td>\n99.76%<\/td>\nProteasome inhibitor, epoxomicin analog<\/td>\n<\/tr>\n
A1934<\/td>\nOprozomib (ONX-0912)<\/td>\n935888-69-0<\/td>\n97.63%<\/td>\nProteasome inhibitor<\/td>\n<\/tr>\n
A1935<\/td>\n5-Aminovaleric acid hydrochloride<\/td>\n660-88-8<\/td>\n98.00%<\/td>\nused for the synthesis of polymers<\/td>\n<\/tr>\n
A1945<\/td>\nBIBR 1532<\/td>\n321674-73-1<\/td>\n99.80%<\/td>\nTelomerase inhibitor,novel and selective<\/td>\n<\/tr>\n
A1947<\/td>\nMEK162 (ARRY-162, ARRY-438162)<\/td>\n606143-89-9<\/td>\n98.17%<\/td>\nMEK1\/2 inhibitor,potent and selective<\/td>\n<\/tr>\n
A1952<\/td>\nNSC 23766<\/td>\n1177865-17-6<\/td>\n98.21%<\/td>\nSelective inhibitor of Rac1-GEF interaction.<\/td>\n<\/tr>\n
A1958<\/td>\nEtomidate<\/td>\n33125-97-2<\/td>\n99.84%<\/td>\nGeneral anesthetic with GABA modulatory and GABA-mimetic actions<\/td>\n<\/tr>\n
A1971<\/td>\nEtoposide<\/td>\n33419-42-0<\/td>\n99.56%<\/td>\nTopo II inhibitor<\/td>\n<\/tr>\n
A1980<\/td>\nSNS-032 (BMS-387032)<\/td>\n345627-80-7<\/td>\n99.49%<\/td>\nCDK inhibitor<\/td>\n<\/tr>\n
A1984<\/td>\nBendamustine HCl<\/td>\n3543-75-7<\/td>\n99.74%<\/td>\nCytostatic agent for non-Hodgkin lymphomas<\/td>\n<\/tr>\n
A1986<\/td>\nNu 6027<\/td>\n220036-08-8<\/td>\n98.00%<\/td>\nATR\/CDK inhibitor, potent and selective<\/td>\n<\/tr>\n
A1987<\/td>\nKi16425<\/td>\n355025-24-0<\/td>\n99.02%<\/td>\nLPA receptor antagonist<\/td>\n<\/tr>\n
A2005<\/td>\nNutlin-3b<\/td>\n675576-97-3<\/td>\n98.48%<\/td>\nMDM2\/p53 inhibitor<\/td>\n<\/tr>\n
A2024<\/td>\nPD168393<\/td>\n194423-15-9<\/td>\n98.00%<\/td>\nEGFR inhibitor<\/td>\n<\/tr>\n
A2025<\/td>\nPlerixafor (AMD3100)<\/td>\n110078-46-1<\/td>\n98.00%<\/td>\nCXCR4 chemokine receptor antagonist<\/td>\n<\/tr>\n
A2033<\/td>\nPQ 401<\/td>\n196868-63-0<\/td>\n98.00%<\/td>\nIGF1R inhibitor,potent and cell-permeable<\/td>\n<\/tr>\n
A2036<\/td>\nDoripenem Hydrate<\/td>\n364622-82-2<\/td>\n99.43%<\/td>\nInjectable antibiotic,ultra-broad spectrum<\/td>\n<\/tr>\n
A2065<\/td>\nIC-87114<\/td>\n371242-69-2<\/td>\n98.00%<\/td>\nPI3K\u03b4 inhibitor<\/td>\n<\/tr>\n
A2067<\/td>\nPI-103<\/td>\n371935-74-9<\/td>\n98.66%<\/td>\nClass I PI3K, mTOR and DNA-PK inhibitor<\/td>\n<\/tr>\n
A2080<\/td>\nPIK-75<\/td>\n372196-77-5<\/td>\n99.40%<\/td>\nInhibitor of PI3K isoform p110\u03b1<\/td>\n<\/tr>\n
A2097<\/td>\nIfosfamide<\/td>\n3778-73-2<\/td>\n98.65%<\/td>\nCytostatic agent<\/td>\n<\/tr>\n
A2098<\/td>\nPRX-08066 Maleic acid<\/td>\n866206-55-5<\/td>\n98.00%<\/td>\n5-HT2B receptor antagonist,potent and selective<\/td>\n<\/tr>\n
A2133<\/td>\nSaracatinib (AZD0530)<\/td>\n379231-04-6<\/td>\n99.86%<\/td>\nSrc\/Abl inhibitor,potent and selective<\/td>\n<\/tr>\n
A2149<\/td>\nBosutinib (SKI-606)<\/td>\n380843-75-4<\/td>\n99.78%<\/td>\nPotent Abl\/Src kinases<\/td>\n<\/tr>\n
A2150<\/td>\nAndarine<\/td>\n401900-40-1<\/td>\n99.78%<\/td>\nAndrogen receptor agonist<\/td>\n<\/tr>\n
A2168<\/td>\nDovitinib (TKI-258, CHIR-258)<\/td>\n405169-16-6<\/td>\n99.81%<\/td>\nMultitargeted RTK inhibitor<\/td>\n<\/tr>\n
A2171<\/td>\nCarboplatin<\/td>\n41575-94-4<\/td>\n99.50%<\/td>\nAntitumor agent that forms platinum-DNA adducts.<\/td>\n<\/tr>\n
A2173<\/td>\nSC 144<\/td>\n895158-95-9<\/td>\n99.21%<\/td>\nGp130 inhibitor<\/td>\n<\/tr>\n
A2174<\/td>\nLenvatinib (E7080)<\/td>\n417716-92-8<\/td>\n99.11%<\/td>\nVEGFR inhibitor<\/td>\n<\/tr>\n
A2187<\/td>\nCladribine<\/td>\n4291-63-8<\/td>\n98.01%<\/td>\nApoptosis inducer in CLL cells<\/td>\n<\/tr>\n
A2198<\/td>\nGenistein<\/td>\n446-72-0<\/td>\n99.24%<\/td>\nER agonist<\/td>\n<\/tr>\n
A2213<\/td>\n17-DMAG (Alvespimycin) HCl<\/td>\n467214-21-7<\/td>\n99.22%<\/td>\nHsp90 inhibitor<\/td>\n<\/tr>\n
A2224<\/td>\nStattic<\/td>\n19983-44-9<\/td>\n99.82%<\/td>\nSTAT3 inhibitor,small-molecule and potent<\/td>\n<\/tr>\n
A2249<\/td>\nT0901317<\/td>\n293754-55-9<\/td>\n99.91%<\/td>\nLiver X receptor agonist,potent and selective<\/td>\n<\/tr>\n
A2251<\/td>\nTivozanib (AV-951)<\/td>\n475108-18-0<\/td>\n98.26%<\/td>\nVEGFR inhibitor,potent and selective<\/td>\n<\/tr>\n
A2278<\/td>\nNVP-AEW541<\/td>\n475489-16-8<\/td>\n98.00%<\/td>\nIGF-IR inhibitor, novel, potent and selective<\/td>\n<\/tr>\n
A2306<\/td>\nEllagic acid<\/td>\n476-66-4<\/td>\n98.39%<\/td>\nCasein kinase 2 (CK2) inhibitor<\/td>\n<\/tr>\n
A2307<\/td>\nPHA-665752<\/td>\n477575-56-7<\/td>\n98.00%<\/td>\nC-Met inhibitor,potent and ATP-competitive<\/td>\n<\/tr>\n
A2308<\/td>\nTAK-438<\/td>\n1260141-27-2<\/td>\n98.00%<\/td>\nBlocker of potassium-competitive acid<\/td>\n<\/tr>\n
A2310<\/td>\nSR9009<\/td>\n1379686-30-2<\/td>\n99.71%<\/td>\nREV-ERB-\u03b1\/\u03b2 Agonist<\/td>\n<\/tr>\n
A2323<\/td>\nTCS 359<\/td>\n301305-73-7<\/td>\n99.26%<\/td>\nPotent FLT3 inhibitor<\/td>\n<\/tr>\n
A2324<\/td>\nDexamethasone (DHAP)<\/td>\n50-02-2<\/td>\n99.95%<\/td>\nGlucocorticoidan; anti-inflammatory<\/td>\n<\/tr>\n
A2343<\/td>\nCyclophosphamide<\/td>\n50-18-0<\/td>\n98.00%<\/td>\nNitrogen mustard alkylating agent and prodrug.<\/td>\n<\/tr>\n
A2355<\/td>\nMercaptopurine (6-MP)<\/td>\n50-44-2<\/td>\n99.72%<\/td>\nPurine synthesis inhibitor<\/td>\n<\/tr>\n
A2402<\/td>\nFloxuridine<\/td>\n50-91-9<\/td>\n99.22%<\/td>\nAntineoplastic antimetabolite<\/td>\n<\/tr>\n
A2415<\/td>\nAcitretin<\/td>\n55079-83-9<\/td>\n99.87%<\/td>\nMetabolite of etretinate<\/td>\n<\/tr>\n
A2431<\/td>\nAcarbose<\/td>\n56180-94-0<\/td>\n98.00%<\/td>\nAlpha-glucosidase inhibitor<\/td>\n<\/tr>\n
A2436<\/td>\nFluoxetine HCl<\/td>\n56296-78-7<\/td>\n99.60%<\/td>\nSerotonin reuptake inhibitor,selective<\/td>\n<\/tr>\n
A2451<\/td>\nEpirubicin HCl<\/td>\n56390-09-1<\/td>\n98.62%<\/td>\nAntibiotic antitumor agent<\/td>\n<\/tr>\n
A2456<\/td>\nPamidronate Disodium<\/td>\n57248-88-1<\/td>\n98.00%<\/td>\nBisphosphonate antiresorptive agent & bone resorption inhibitor<\/td>\n<\/tr>\n
A2477<\/td>\nTyrphostin AG 1296<\/td>\n146535-11-7<\/td>\n99.90%<\/td>\nPDGFR inhibitor,selective and ATP-competitive<\/td>\n<\/tr>\n
A2486<\/td>\nMalotilate<\/td>\n59937-28-9<\/td>\n98.72%<\/td>\nStimulates hepatocyte regeneration<\/td>\n<\/tr>\n
A2487<\/td>\nOdanacatib (MK-0822)<\/td>\n603139-19-1<\/td>\n99.04%<\/td>\nCathepsin K,potent and selective<\/td>\n<\/tr>\n
A2489<\/td>\nLeucovorin Calcium<\/td>\n6035-45-6<\/td>\n98.00%<\/td>\nDerivative of folic acid<\/td>\n<\/tr>\n
A2510<\/td>\nAmpicillin sodium<\/td>\n69-52-3<\/td>\n98.00%<\/td>\n\u03b2-lactam antibiotic<\/td>\n<\/tr>\n
A2511<\/td>\nCarbenicillin, Disodium Salt<\/td>\n4800-94-6<\/td>\n98.00%<\/td>\nInhibits the cell-wall synthesis,antibiotic<\/td>\n<\/tr>\n
A2512<\/td>\nChloramphenicol<\/td>\n56-75-7<\/td>\n99.52%<\/td>\nInhibits translation(blocking peptidyl transferase)<\/td>\n<\/tr>\n
A2513<\/td>\nGeneticin, G-418 Sulfate<\/td>\n108321-42-2<\/td>\n98.00%<\/td>\nAminoglycosidic antibiotic<\/td>\n<\/tr>\n
A2515<\/td>\nHygromycin B<\/td>\n31282-04-9<\/td>\n98.00%<\/td>\nSuitable for mammalian cell selection<\/td>\n<\/tr>\n
A2516<\/td>\nKanamycin Sulfate<\/td>\n25389-94-0<\/td>\n98.00%<\/td>\nWater-soluble antibiotic<\/td>\n<\/tr>\n
A2517<\/td>\nTetracycline Hydrochloride<\/td>\n64-75-5<\/td>\n98.48%<\/td>\nBacteriostatic antibiotics<\/td>\n<\/tr>\n
A2521<\/td>\nVE-821<\/td>\n1232410-49-9<\/td>\n98.03%<\/td>\nATR kinase inhibitor<\/td>\n<\/tr>\n
A2531<\/td>\nFluoroorotic Acid, Ultra Pure<\/td>\n703-95-7<\/td>\n99.62%<\/td>\n5-Fluoroorotic acid<\/td>\n<\/tr>\n
A2539<\/td>\nX-Gal<\/td>\n7240-90-6<\/td>\n99.48%<\/td>\nSubstrate for \u03b2-galactosidase,used in blue\/white screening<\/td>\n<\/tr>\n
A2548<\/td>\nCarmofur<\/td>\n61422-45-5<\/td>\n98.00%<\/td>\nCytostatic derivative of fluorouracilm,antineoplatic agent<\/td>\n<\/tr>\n
A2552<\/td>\nQuercetin dihydrate<\/td>\n6151-25-3<\/td>\n98.23%<\/td>\nPLA2 and PI 3-kinase inhibitor<\/td>\n<\/tr>\n
A2559<\/td>\nAltretamine<\/td>\n645-05-6<\/td>\n99.13%<\/td>\nAntineoplastic agent<\/td>\n<\/tr>\n
A2570<\/td>\nLeupeptin, Microbial<\/td>\n103476-89-7<\/td>\n98.00%<\/td>\nInhibitor of serine and cysteine proteases<\/td>\n<\/tr>\n
A2571<\/td>\nPepstatin A<\/td>\n26305-03-3<\/td>\n98.96%<\/td>\nAspartic proteinases inhibitor<\/td>\n<\/tr>\n
A2573<\/td>\nAEBSF.HCl<\/td>\n30827-99-7<\/td>\n99.68%<\/td>\nSerine protease inhibitor<\/td>\n<\/tr>\n
A2574<\/td>\nAprotinin<\/td>\n9087-70-1<\/td>\n98.00%<\/td>\nInhibitor of bovine pancreatic trypsin<\/td>\n<\/tr>\n
A2575<\/td>\nBestatin<\/td>\n58970-76-6<\/td>\n98.00%<\/td>\nAminopeptidase inhibitor<\/td>\n<\/tr>\n
A2576<\/td>\nE-64<\/td>\n66701-25-5<\/td>\n98.00%<\/td>\nCysteine protease inhibitor,irriversible<\/td>\n<\/tr>\n
A2577<\/td>\nBatimastat (BB-94)<\/td>\n130370-60-4<\/td>\n98.32%<\/td>\nMMP inhibitor<\/td>\n<\/tr>\n
A2578<\/td>\nClasto-Lactacystin \u03b2-lactone<\/td>\n154226-60-5<\/td>\n\u226595.00%<\/td>\nProteasome inhibitor<\/td>\n<\/tr>\n
A2580<\/td>\nElastase Inhibitor, SPCK<\/td>\n65144-34-5<\/td>\n98.00%<\/td>\nHLE inhibitor<\/td>\n<\/tr>\n
A2583<\/td>\nLactacystin (Synthetic)<\/td>\n133343-34-7<\/td>\n98.00%<\/td>\nProteasome inhibitor<\/td>\n<\/tr>\n
A2585<\/td>\nMG-132<\/td>\n133407-82-6<\/td>\n97.56%<\/td>\nProteasome inhibitor, Cell permeable, reversible<\/td>\n<\/tr>\n
A2586<\/td>\nNafamostat Mesylate(FUT-175)<\/td>\n82956-11-4<\/td>\n99.79%<\/td>\nSerine protease inhibitor<\/td>\n<\/tr>\n
A2587<\/td>\nPMSF<\/td>\n329-98-6<\/td>\n99.78%<\/td>\nSerine proteinases inhibitor, irreversible<\/td>\n<\/tr>\n
A2588<\/td>\nPPACK Dihydrochloride<\/td>\n142036-63-3<\/td>\n99.10%<\/td>\nThrombin inhibitor<\/td>\n<\/tr>\n
A2597<\/td>\nBrivanib (BMS-540215)<\/td>\n649735-46-6<\/td>\n99.59%<\/td>\nVEGFR-2 inhibitor,ATP-competitive<\/td>\n<\/tr>\n
A2600<\/td>\n(-)-Epigallocatechin gallate (EGCG)<\/td>\n989-51-5<\/td>\n99.12%<\/td>\nAntioxidant, antiangiogenic and antitumor agent<\/td>\n<\/tr>\n
A2601<\/td>\nAclacinomycin A<\/td>\n57576-44-0<\/td>\n98.00%<\/td>\nTopoisomerase I and II inhibitor<\/td>\n<\/tr>\n
A2602<\/td>\nCalpain Inhibitor I, ALLN<\/td>\n110044-82-1<\/td>\n98.00%<\/td>\nCalpain I\/II\/ B\/L inhibitor<\/td>\n<\/tr>\n
A2603<\/td>\nCalpain Inhibitor II, ALLM<\/td>\n136632-32-1<\/td>\n98.00%<\/td>\nCalpain inhibitor<\/td>\n<\/tr>\n
A2604<\/td>\nCelastrol<\/td>\n34157-83-0<\/td>\n98.67%<\/td>\nAntioxidant, anti-inflammatory and immunosuppressive agent<\/td>\n<\/tr>\n
A2606<\/td>\nEpoxomicin<\/td>\n134381-21-8<\/td>\n97.92%<\/td>\nProteasome inhibitor<\/td>\n<\/tr>\n
A2610<\/td>\nFenbendazole<\/td>\n43210-67-9<\/td>\n99.57%<\/td>\nFor pinworm treatment in animals<\/td>\n<\/tr>\n
A2612<\/td>\nMG-115<\/td>\n133407-86-0<\/td>\n98.00%<\/td>\nPotent reversible proteasome inhibitor<\/td>\n<\/tr>\n
A2614<\/td>\nBortezomib (PS-341)<\/td>\n179324-69-7<\/td>\n99.89%<\/td>\nProteasome Inhibitor<\/td>\n<\/tr>\n
A2623<\/td>\nVU 0364439<\/td>\n1246086-78-1<\/td>\n98.00%<\/td>\nPositive allosteric mGluR-4 modulator<\/td>\n<\/tr>\n
A2633<\/td>\nBrivanib Alaninate (BMS-582664)<\/td>\n649735-63-7<\/td>\n98.00%<\/td>\nVEGFR2 inhibitor,ATP-competitive<\/td>\n<\/tr>\n
A2664<\/td>\nVX-661<\/td>\n1152311-62-0<\/td>\n99.88%<\/td>\nF508del CFTR corrector<\/td>\n<\/tr>\n
A2673<\/td>\nAG-1024<\/td>\n65678-07-1<\/td>\n98.00%<\/td>\nSelective IGF-1R inhibitor<\/td>\n<\/tr>\n
A2678<\/td>\nSU11274<\/td>\n658084-23-2<\/td>\n\u226595.00%<\/td>\nC-Met inhibitor,potent and selective<\/td>\n<\/tr>\n
A2681<\/td>\nTGX-221<\/td>\n663619-89-4<\/td>\n98.91%<\/td>\nPI3K\u03b2 inhibitor,potent,selective and ATP competitive<\/td>\n<\/tr>\n
A2689<\/td>\nButein<\/td>\n487-52-5<\/td>\n98.00%<\/td>\nProtein kinase inhibitor<\/td>\n<\/tr>\n
A2700<\/td>\n10Panx<\/td>\n955091-53-9<\/td>\n99.29%<\/td>\nPanx-1 mimetic inhibitor<\/td>\n<\/tr>\n
A2701<\/td>\nScrambled 10Panx<\/td>\n1315378-72-3<\/td>\n98.68%<\/td>\nPanx-1 mimetic inhibitory peptide, blocks pannexin-1 gap junctions<\/td>\n<\/tr>\n
A2754<\/td>\nTG100-115<\/td>\n677297-51-7<\/td>\n98.02%<\/td>\nPI3K\u03b3\/PI3K\u03b4 inhibitor<\/td>\n<\/tr>\n
A2782<\/td>\nAmonafide<\/td>\n69408-81-7<\/td>\n98.00%<\/td>\nDNA intercalator,Topo II inhibitor<\/td>\n<\/tr>\n
A2806<\/td>\nBX-912<\/td>\n702674-56-4<\/td>\n95.55%<\/td>\nPDK1 inhibitor,potent and ATP-competitive<\/td>\n<\/tr>\n
A2813<\/td>\nIvermectin<\/td>\n70288-86-7<\/td>\n98.00%<\/td>\nNAChR\/purinergic P2X4 receptor modulator<\/td>\n<\/tr>\n
A2822<\/td>\nAC480 (BMS-599626)<\/td>\n714971-09-2<\/td>\n98.00%<\/td>\nHER1\/2 inhibitor,selective and efficacious<\/td>\n<\/tr>\n
A2838<\/td>\nOSI-930<\/td>\n728033-96-3<\/td>\n99.58%<\/td>\nInhibitor of Kit, KDR, Flt, CSF-1R, c-Raf and Lck<\/td>\n<\/tr>\n
A2842<\/td>\nMelatonin<\/td>\n73-31-4<\/td>\n99.81%<\/td>\nMelatonin receptors agonist<\/td>\n<\/tr>\n
A2845<\/td>\nOmeprazole<\/td>\n73590-58-6<\/td>\n97.37%<\/td>\nH+,K+-ATPase inhibitor<\/td>\n<\/tr>\n
A2846<\/td>\nOSU-03012 (AR-12)<\/td>\n742112-33-0<\/td>\n99.43%<\/td>\nPotent PDK1 inhibitor<\/td>\n<\/tr>\n
A2852<\/td>\nLeflunomide<\/td>\n75706-12-6<\/td>\n99.69%<\/td>\nAHR agonist,immunosuppressive agent<\/td>\n<\/tr>\n
A2884<\/td>\nDoxazosin Mesylate<\/td>\n77883-43-3<\/td>\n99.82%<\/td>\n\u03b11-adrenergic receptor antagonist<\/td>\n<\/tr>\n
A2890<\/td>\nNepafenac<\/td>\n78281-72-8<\/td>\n98.00%<\/td>\nCOX-1 and COX-2 inhibitor<\/td>\n<\/tr>\n
A2917<\/td>\nFlumazenil<\/td>\n78755-81-4<\/td>\n99.85%<\/td>\nBenzodiazepine antagonist<\/td>\n<\/tr>\n
A2942<\/td>\nMasitinib (AB1010)<\/td>\n790299-79-5<\/td>\n99.60%<\/td>\nTyrosine kinase inhibitor, potent and selective<\/td>\n<\/tr>\n
A2949<\/td>\nLinifanib (ABT-869)<\/td>\n796967-16-3<\/td>\n99.62%<\/td>\nVEGFR\/PDGFR inhibitor<\/td>\n<\/tr>\n
A2960<\/td>\nLoratadine<\/td>\n79794-75-5<\/td>\n98.24%<\/td>\nPeripheral HH1R antagonist<\/td>\n<\/tr>\n
A2974<\/td>\nForetinib (GSK1363089)<\/td>\n849217-64-7<\/td>\n98.36%<\/td>\nVEGF and HGF receptor inhibitor<\/td>\n<\/tr>\n
A2977<\/td>\nCabozantinib (XL184, BMS-907351)<\/td>\n849217-68-1<\/td>\n98.60%<\/td>\nVEGFR2\/Met\/Ret\/Kit\/FLT\/\/AXL inhibitor<\/td>\n<\/tr>\n
A2986<\/td>\nADL5859 HCl<\/td>\n850173-95-4<\/td>\n99.16%<\/td>\n\u03b4-opioid receptor agonist,selective<\/td>\n<\/tr>\n
A3001<\/td>\nPCI-32765 (Ibrutinib)<\/td>\n936563-96-1<\/td>\n99.39%<\/td>\nBruton’s tyrosine kinase (BTK) inhibitor<\/td>\n<\/tr>\n
A3002<\/td>\nABT-888 (Veliparib)<\/td>\n912444-00-9<\/td>\n99.87%<\/td>\nPotent PARP inhibitor<\/td>\n<\/tr>\n
A3003<\/td>\nMDV3100 (Enzalutamide)<\/td>\n915087-33-1<\/td>\n99.78%<\/td>\nAndrogen receptor antagonist<\/td>\n<\/tr>\n
A3004<\/td>\nVemurafenib (PLX4032, RG7204)<\/td>\n918504-65-1<\/td>\n98.48%<\/td>\nBRAF kinase inhibitor<\/td>\n<\/tr>\n
A3005<\/td>\nCAL-101 (Idelalisib, GS-1101)<\/td>\n870281-82-6<\/td>\n99.91%<\/td>\nPI3K inhibitor<\/td>\n<\/tr>\n
A3006<\/td>\nGDC-0068 (RG7440)<\/td>\n1001264-89-6<\/td>\n99.06%<\/td>\nPan-AKT inhibitor,highly selective<\/td>\n<\/tr>\n
A3007<\/td>\nABT-263 (Navitoclax)<\/td>\n923564-51-6<\/td>\n98.02%<\/td>\nPotent Bcl-2 family inhibitor, inhibits Bcl-2, Bcl-xL, and Bcl-w<\/td>\n<\/tr>\n
A3008<\/td>\nY-27632 dihydrochloride<\/td>\n146986-50-7;129830-38-2<\/td>\n99.08%<\/td>\nROCK1 inhibitor<\/td>\n<\/tr>\n
A3009<\/td>\nSorafenib<\/td>\n284461-73-0<\/td>\n99.87%<\/td>\nRaf kinases and tyrosine kinases inhibitor<\/td>\n<\/tr>\n
A3010<\/td>\nMK-2206 dihydrochloride<\/td>\n1032350-13-2<\/td>\n99.59%<\/td>\nAkt1\/2\/3 inhibitor<\/td>\n<\/tr>\n
A3011<\/td>\nCHIR-99021 (CT99021)<\/td>\n252917-06-9<\/td>\n98.32%<\/td>\nGSK-3 inhibitor, Cell-permeable, ATP-competitive<\/td>\n<\/tr>\n
A3012<\/td>\nRuxolitinib (INCB018424)<\/td>\n941678-49-5<\/td>\n99.64%<\/td>\nJAK inhibitor<\/td>\n<\/tr>\n
A3013<\/td>\nPD0325901<\/td>\n391210-10-9<\/td>\n99.74%<\/td>\nMEK inhibitor<\/td>\n<\/tr>\n
A3014<\/td>\nBGJ398<\/td>\n872511-34-7<\/td>\n99.74%<\/td>\nFGFR inhibitor ,potent and selective<\/td>\n<\/tr>\n
A3015<\/td>\nBKM120<\/td>\n944396-07-0<\/td>\n98.01%<\/td>\nInhibitor of pan-Class I PI3K<\/td>\n<\/tr>\n
A3016<\/td>\nPLX-4720<\/td>\n918505-84-7<\/td>\n98.70%<\/td>\nBRAF kinase inhibitor<\/td>\n<\/tr>\n
A3017<\/td>\nDasatinib (BMS-354825)<\/td>\n302962-49-8<\/td>\n98.09%<\/td>\nSrc and BCR-Abl inhibitor<\/td>\n<\/tr>\n
A3018<\/td>\nTrametinib (GSK1120212)<\/td>\n871700-17-3<\/td>\n98.98%<\/td>\nMEK1 and MEK2 inhibitor, potent and selective<\/td>\n<\/tr>\n
A3019<\/td>\nAT-406 (SM-406)<\/td>\n1071992-99-8<\/td>\n98.00%<\/td>\nIAP inhibitor<\/td>\n<\/tr>\n
A3021<\/td>\nGDC-0449 (Vismodegib)<\/td>\n879085-55-9<\/td>\n99.64%<\/td>\nHedgehog antagonist,potent and selective<\/td>\n<\/tr>\n
A3022<\/td>\nPazopanib (GW-786034)<\/td>\n444731-52-6<\/td>\n98.81%<\/td>\nVEGFR\/PDGFR\/FGFR inhibitor<\/td>\n<\/tr>\n
A3023<\/td>\nP005091<\/td>\n882257-11-6<\/td>\n99.67%<\/td>\nUbiquitin-specific protease 7 (USP7) inhibitor<\/td>\n<\/tr>\n
A3100<\/td>\n(+)-MK 801<\/td>\n70449-94-4<\/td>\n99.38%<\/td>\nPotent NMDA antagonist<\/td>\n<\/tr>\n
A3104<\/td>\n(E)-2-Decenoic acid<\/td>\n334-49-6<\/td>\n98.00%<\/td>\nFatty acid identified in royal jelly<\/td>\n<\/tr>\n
A3108<\/td>\n17 alpha-propionate<\/td>\n19608-29-8<\/td>\n98.00%<\/td>\nAndrogen antagonist<\/td>\n<\/tr>\n
A3111<\/td>\n1alpha, 25-Dihydroxy VD2-D6<\/td>\n216244-04-1<\/td>\n98.00%<\/td>\nDeuterated form of vitamin D<\/td>\n<\/tr>\n
A3115<\/td>\n24, 25-Dihydroxy VD3<\/td>\n40013-87-4<\/td>\n98.00%<\/td>\nVitamin D analogue<\/td>\n<\/tr>\n
A3118<\/td>\n3,3′-Diindolylmethane<\/td>\n1968-05-4<\/td>\n99.69%<\/td>\nAnticancer and antineoplastic agent<\/td>\n<\/tr>\n
A3119<\/td>\n360A<\/td>\n794458-56-3<\/td>\n98.00%<\/td>\nG-quadruplex structures inhibitor<\/td>\n<\/tr>\n
A3120<\/td>\n360A iodide<\/td>\n737763-37-0<\/td>\n98.56%<\/td>\nG-quadruplex structures inhibitor<\/td>\n<\/tr>\n
A3122<\/td>\nPI4KIII beta inhibitor 3<\/td>\n1245319-54-3<\/td>\n98.00%<\/td>\nPI4KIII beta inhibitor<\/td>\n<\/tr>\n
A3123<\/td>\n4′-Demethylepipodophyllotoxin<\/td>\n6559-91-7<\/td>\n99.32%<\/td>\nAnti-cancer drug<\/td>\n<\/tr>\n
A3124<\/td>\n5-hydroxypyrazine-2-carboxylic acid<\/td>\n34604-60-9<\/td>\n99.15%<\/td>\nMetabolite of pyrazinamide (PZA)<\/td>\n<\/tr>\n
A3125<\/td>\n5-Iodotubercidin<\/td>\n24386-93-4<\/td>\n98.34%<\/td>\nAdenosine kinase inhibitor,potent<\/td>\n<\/tr>\n
A3126<\/td>\n5-R-Rivaroxaban<\/td>\n865479-71-6<\/td>\n99.49%<\/td>\nFactor Xa (FXa) inhibitor<\/td>\n<\/tr>\n
A3130<\/td>\nA 438079<\/td>\n899507-36-9<\/td>\n98.00%<\/td>\nP2X7 receptor antagonist,competitive and selective<\/td>\n<\/tr>\n
A3131<\/td>\nA 438079 hydrochloride<\/td>\n899431-18-6<\/td>\n99.59%<\/td>\nP2X7 receptor antagonist,competitive and selective<\/td>\n<\/tr>\n
A3132<\/td>\nA 77-01<\/td>\n607737-87-1<\/td>\n99.50%<\/td>\nPotent ALK5 inhibitor<\/td>\n<\/tr>\n
A3133<\/td>\nA 83-01<\/td>\n909910-43-6<\/td>\n99.24%<\/td>\nALK-5 inhibitor<\/td>\n<\/tr>\n
A3134<\/td>\nA-317491<\/td>\n475205-49-3<\/td>\n98.53%<\/td>\nP2X3 and P2X2\/3 receptor antagonist<\/td>\n<\/tr>\n
A3135<\/td>\nA-443654<\/td>\n552325-16-3<\/td>\n99.79%<\/td>\nAkt inhibitor,potent and selective<\/td>\n<\/tr>\n
A3136<\/td>\nA-740003<\/td>\n861393-28-4<\/td>\n98.24%<\/td>\nP2X7 receptor antagonist<\/td>\n<\/tr>\n
A3138<\/td>\nA-867744<\/td>\n1000279-69-5<\/td>\n98.00%<\/td>\nAllosteric Modulator<\/td>\n<\/tr>\n
A3139<\/td>\nAbacavir<\/td>\n136470-78-5<\/td>\n99.89%<\/td>\nInhibitor of HIV reverse transcriptase<\/td>\n<\/tr>\n
A3142<\/td>\nAcamprosate calcium<\/td>\n77337-73-6<\/td>\n99.78%<\/td>\nGABA receptor agonist and modulator of glutamatergic systems<\/td>\n<\/tr>\n
A3143<\/td>\nAdarotene<\/td>\n496868-77-0<\/td>\n99.24%<\/td>\nApoptosis inducer\/DNA damage agent<\/td>\n<\/tr>\n
A3145<\/td>\nAfatinib dimaleate<\/td>\n850140-73-7<\/td>\n99.49%<\/td>\nEGFR inhibitor<\/td>\n<\/tr>\n
A3146<\/td>\nAGI-6780<\/td>\n1432660-47-3<\/td>\n98.63%<\/td>\nIDH2\/R140Q mutation inhibitor<\/td>\n<\/tr>\n
A3147<\/td>\nAH 6809<\/td>\n33458-93-4<\/td>\n98.00%<\/td>\nEP and DP receptor antagonist<\/td>\n<\/tr>\n
A3148<\/td>\nAIM-100<\/td>\n873305-35-2<\/td>\n98.95%<\/td>\nAck1 inhibitor<\/td>\n<\/tr>\n
A3149<\/td>\nAKT inhibitor VIII<\/td>\n612847-09-3<\/td>\n99.73%<\/td>\nAllosteric Akt kinase inhibitor<\/td>\n<\/tr>\n
A3151<\/td>\nAlarelin Acetate<\/td>\n79561-22-1<\/td>\n99.88%<\/td>\nSynthetic GnRH agonist<\/td>\n<\/tr>\n
A3153<\/td>\nAliskiren<\/td>\n173334-57-1<\/td>\n98.95%<\/td>\nDirect renin inhibitor<\/td>\n<\/tr>\n
A3155<\/td>\nALK inhibitor 2<\/td>\n761438-38-4<\/td>\n98.00%<\/td>\nALK inhibitor, novel and selective<\/td>\n<\/tr>\n
A3156<\/td>\nAlogliptin Benzoate<\/td>\n850649-62-6<\/td>\n98.00%<\/td>\nDPP-4 inhibitor,selective and potent,antidiabetic drug<\/td>\n<\/tr>\n
A3157<\/td>\nAlosetron<\/td>\n122852-42-0<\/td>\n98.00%<\/td>\n5-HT3 receptor antagonist<\/td>\n<\/tr>\n
A3159<\/td>\nAlosetron Hydrochloride<\/td>\n122852-69-1<\/td>\n98.91%<\/td>\n5-HT3 receptor antagonist,potent and highly selective<\/td>\n<\/tr>\n
A3162<\/td>\nAlvimopan<\/td>\n156053-89-3<\/td>\n99.67%<\/td>\nMu-opioid receptors antagonist<\/td>\n<\/tr>\n
A3163<\/td>\nAlvimopan dihydrate<\/td>\n170098-38-1<\/td>\n98.00%<\/td>\n\u03bc-opioid receptor antagonist,peripherally acting<\/td>\n<\/tr>\n
A3165<\/td>\nALW-II-41-27<\/td>\n1186206-79-0<\/td>\n97.45%<\/td>\nEph receptor inhibitor<\/td>\n<\/tr>\n
A3166<\/td>\nAM095<\/td>\n1345614-59-6<\/td>\n98.14%<\/td>\nPotent LPA1 receptor antagonist<\/td>\n<\/tr>\n
A3167<\/td>\nAM-095 free base<\/td>\n1228690-36-5<\/td>\n98.12%<\/td>\nPotent LPA1 receptor antagonist<\/td>\n<\/tr>\n
A3169<\/td>\nAM679<\/td>\n1206880-66-1<\/td>\n98.00%<\/td>\nFLAP inhibitor<\/td>\n<\/tr>\n
A3170<\/td>\nAM966<\/td>\n1228690-19-4<\/td>\n99.69%<\/td>\nLPA1 antagonist, oral active, high affinity, selective,<\/td>\n<\/tr>\n
A3171<\/td>\nAmadacycline<\/td>\n389139-89-3<\/td>\n99.46%<\/td>\nTetracycline antibiotic<\/td>\n<\/tr>\n
A3173<\/td>\nAMD-070<\/td>\n558447-26-0<\/td>\n98.00%<\/td>\nCXCR4 antagonist,potent and selective<\/td>\n<\/tr>\n
A3174<\/td>\nAMD-070 hydrochloride<\/td>\n880549-30-4<\/td>\n98.00%<\/td>\nCXCR4 antagonist,potent and selective<\/td>\n<\/tr>\n
A3176<\/td>\nAmpalex<\/td>\n154235-83-3<\/td>\n98.54%<\/td>\nAmpakine and nootropic<\/td>\n<\/tr>\n
A3177<\/td>\nAN-2690<\/td>\n174671-46-6<\/td>\n98.60%<\/td>\nAntifungal agent<\/td>\n<\/tr>\n
A3178<\/td>\nAN-2728<\/td>\n906673-24-3<\/td>\n99.33%<\/td>\nPDE4 inhibitor,anti-inflammatory compound<\/td>\n<\/tr>\n
A3179<\/td>\nAnamorelin<\/td>\n249921-19-5<\/td>\n99.68%<\/td>\nGhrelin receptor agonist, synthetic, orally active<\/td>\n<\/tr>\n
A3182<\/td>\nAnguizole<\/td>\n442666-98-0<\/td>\n98.00%<\/td>\nInhibitor of HCV replication<\/td>\n<\/tr>\n
A3184<\/td>\nAR-A014418<\/td>\n487021-52-3<\/td>\n98.34%<\/td>\nGSK3\u03b2 inhibitor, ATP-competitive and selective<\/td>\n<\/tr>\n
A3185<\/td>\nAR-C155858<\/td>\n496791-37-8<\/td>\n99.52%<\/td>\nMCT1 and MCT2 inhibitor<\/td>\n<\/tr>\n
A3188<\/td>\nARRY-520 R enantiomer<\/td>\n885060-08-2<\/td>\n98.00%<\/td>\nKSP inhibitor<\/td>\n<\/tr>\n
A3189<\/td>\nAS 602801<\/td>\n848344-36-5<\/td>\n98.72%<\/td>\nJun Kinase Inhibitor<\/td>\n<\/tr>\n
A3190<\/td>\nASC-J9<\/td>\n52328-98-0<\/td>\n98.00%<\/td>\nAR degradation enhancer,antiumor agent<\/td>\n<\/tr>\n
A3191<\/td>\nAscomycin(FK 520)<\/td>\n104987-12-4<\/td>\n98.00%<\/td>\nMacrolide immunosuppressant,FK-520 analog<\/td>\n<\/tr>\n
A3192<\/td>\nAsenapine hydrochloride<\/td>\n1412458-61-7<\/td>\n98.00%<\/td>\nAtypical antipsychotic<\/td>\n<\/tr>\n
A3193<\/td>\nASP3026<\/td>\n1097917-15-1<\/td>\n99.38%<\/td>\nALK inhibitor,potent and selective<\/td>\n<\/tr>\n
A3194<\/td>\nAST 487<\/td>\n630124-46-8<\/td>\n99.29%<\/td>\nRET kinase inhibitor<\/td>\n<\/tr>\n
A3195<\/td>\nAsunaprevir (BMS-650032)<\/td>\n630420-16-5<\/td>\n99.80%<\/td>\nNS3 protease inhibitor<\/td>\n<\/tr>\n
A3196<\/td>\nAT-101<\/td>\n90141-22-3<\/td>\n98.00%<\/td>\nBH3-mimetic,gossypol enantiomer<\/td>\n<\/tr>\n
A3197<\/td>\nAT7519 Hydrochloride<\/td>\n902135-91-5<\/td>\n99.80%<\/td>\nMulti-CDK inhibitor<\/td>\n<\/tr>\n
A3198<\/td>\nAT7519 trifluoroacetate<\/td>\n1431697-85-6<\/td>\n98.00%<\/td>\nCDK\/cyclin inhibitor<\/td>\n<\/tr>\n
A3199<\/td>\nAT7867 dihydrochloride<\/td>\n1431697-86-7<\/td>\n98.00%<\/td>\nAkt1 and p70S6K\/PKA inhibitor<\/td>\n<\/tr>\n
A3201<\/td>\nAtrasentan hydrochloride<\/td>\n195733-43-8<\/td>\n98.00%<\/td>\nEndothelin receptor antagonist<\/td>\n<\/tr>\n
A3202<\/td>\nAvermectin B1<\/td>\n71751-41-2<\/td>\n98.00%<\/td>\nInsecticide<\/td>\n<\/tr>\n
A3206<\/td>\nAVL-292<\/td>\n1202757-89-8<\/td>\n98.27%<\/td>\nBtk inhibitor<\/td>\n<\/tr>\n
A3208<\/td>\nAvosentan<\/td>\n290815-26-8<\/td>\n98.00%<\/td>\nETA receptor antagonist<\/td>\n<\/tr>\n
A3209<\/td>\nAXL1717<\/td>\n477-47-4<\/td>\n98.07%<\/td>\nIGF-1R inhibitor,orally active<\/td>\n<\/tr>\n
A3210<\/td>\nAZ20<\/td>\n1233339-22-4<\/td>\n99.93%<\/td>\nATR inhibitor,potent and selective<\/td>\n<\/tr>\n
A3214<\/td>\nAZD1152<\/td>\n722543-31-9<\/td>\n98.78%<\/td>\nAurora B kinase inhibitor,highly potent and selective<\/td>\n<\/tr>\n
A3215<\/td>\nAZD7687<\/td>\n1166827-44-6<\/td>\n98.00%<\/td>\nDGAT inhibitor,potent and selective<\/td>\n<\/tr>\n
A3216<\/td>\nBalaglitazone<\/td>\n199113-98-9<\/td>\n99.62%<\/td>\nPPAR-\u03b3 partial agonist<\/td>\n<\/tr>\n
A3217<\/td>\nBalapiravir<\/td>\n690270-29-2<\/td>\n98.00%<\/td>\nPolymerase inhibitor,anti-HCV<\/td>\n<\/tr>\n
A3218<\/td>\nBAM7<\/td>\n331244-89-4<\/td>\n98.00%<\/td>\nBAX activator,direct and selective<\/td>\n<\/tr>\n
A3219<\/td>\nBAN ORL 24<\/td>\n475150-69-7<\/td>\n98.00%<\/td>\nNOP receptor antagonist, potent and selective<\/td>\n<\/tr>\n
A3220<\/td>\nBardoxolone<\/td>\n218600-44-3<\/td>\n99.55%<\/td>\nOnce-a-day treatment for CKD<\/td>\n<\/tr>\n
A3221<\/td>\nBardoxolone methyl<\/td>\n218600-53-4<\/td>\n98.75%<\/td>\nIKK inhibitor, potent antioxidant inflammation modulator<\/td>\n<\/tr>\n
A3222<\/td>\nBaricitinib phosphate<\/td>\n1187595-84-1<\/td>\n99.59%<\/td>\nJAK1\/JAK2 inhibitor<\/td>\n<\/tr>\n
A3227<\/td>\nBAY 61-3606<\/td>\n732983-37-8<\/td>\n98.45%<\/td>\nSyk Inhibitor<\/td>\n<\/tr>\n
A3228<\/td>\nBAY 61-3606 dihydrochloride<\/td>\n648903-57-5<\/td>\n98.00%<\/td>\nSyk tyrosine kinase inhibitor<\/td>\n<\/tr>\n
A3230<\/td>\nBay 65-1942 HCl salt<\/td>\n600734-06-3<\/td>\n98.00%<\/td>\nIKK\u03b2 kinase inhibitor<\/td>\n<\/tr>\n
A3232<\/td>\nBazedoxifene<\/td>\n198481-32-2<\/td>\n98.00%<\/td>\nEstrogen receptor modulator<\/td>\n<\/tr>\n
A3236<\/td>\nBenfotiamine<\/td>\n22457-89-2<\/td>\n99.76%<\/td>\nDrug for painful nerve condition<\/td>\n<\/tr>\n
A3237<\/td>\nBetulinic acid<\/td>\n472-15-1<\/td>\n98.00%<\/td>\nAnti-HIV and antitumor compound,pentacyclic triterpenoid<\/td>\n<\/tr>\n
A3238<\/td>\nBEZ235 Tosylate<\/td>\n1028385-32-1<\/td>\n98.28%<\/td>\nMTOR\/P13K inhibitor<\/td>\n<\/tr>\n
A3239<\/td>\nB-HT 920<\/td>\n36085-73-1<\/td>\n98.00%<\/td>\nD2 receptor agonist<\/td>\n<\/tr>\n
A3240<\/td>\nBIBX 1382<\/td>\n196612-93-8<\/td>\n98.00%<\/td>\nEGFR inhibitor,potent and selective<\/td>\n<\/tr>\n
A3241<\/td>\nBilobalide<\/td>\n33570-04-6<\/td>\n98.00%<\/td>\nNeuroprotective agent<\/td>\n<\/tr>\n
A3242<\/td>\nBitopertin<\/td>\n845614-11-1<\/td>\n99.70%<\/td>\nGlycine reuptake inhibitor(GlyT1)<\/td>\n<\/tr>\n
A3244<\/td>\nBivalirudin Trifluoroacetate<\/td>\n128270-60-0<\/td>\n98.07%<\/td>\nReversible thrombin inhibitor<\/td>\n<\/tr>\n
A3246<\/td>\nBMN-673 8R,9S<\/td>\n1207456-00-5<\/td>\n99.75%<\/td>\nInactive form of BMN 673, used as negative control<\/td>\n<\/tr>\n
A3248<\/td>\nBMS345541 hydrochloride<\/td>\n547757-23-3<\/td>\n99.57%<\/td>\nIKK inhibitor,highly selective<\/td>\n<\/tr>\n
A3250<\/td>\nBMS-509744<\/td>\n439575-02-7<\/td>\n98.00%<\/td>\nItk inhibitor,potent and selective<\/td>\n<\/tr>\n
A3252<\/td>\nBMS-599626 Hydrochloride<\/td>\n873837-23-1<\/td>\n99.58%<\/td>\nEGFR\/HER2 inhibitor,potent and selective<\/td>\n<\/tr>\n
A3253<\/td>\nBMS-626529<\/td>\n701213-36-7<\/td>\n98.01%<\/td>\nHIV-1 attachment inhibitor<\/td>\n<\/tr>\n
A3254<\/td>\nBMS-663068<\/td>\n864953-29-7<\/td>\n98.00%<\/td>\nHIV-1 attachment inhibitor<\/td>\n<\/tr>\n
A3256<\/td>\nBMS-690514<\/td>\n859853-30-8<\/td>\n98.00%<\/td>\nHER\/EGFR inhibitor<\/td>\n<\/tr>\n
A3257<\/td>\nBMS-790052 dihydrochloride<\/td>\n1009119-65-6<\/td>\n99.81%<\/td>\nHCV NS5A inhibitor<\/td>\n<\/tr>\n
A3258<\/td>\nBMS-833923<\/td>\n1059734-66-5<\/td>\n99.84%<\/td>\nSmoothened inhibitor<\/td>\n<\/tr>\n
A3259<\/td>\nBMS-927711<\/td>\n1289023-67-1<\/td>\n98.99%<\/td>\nCGRP receptor antagonist<\/td>\n<\/tr>\n
A3260<\/td>\nBMX-IN-1<\/td>\n1431525-23-3<\/td>\n97.99%<\/td>\nBMX (also termed ETK) kinase inhibitor<\/td>\n<\/tr>\n
A3261<\/td>\nBoceprevir<\/td>\n394730-60-0<\/td>\n98.00%<\/td>\nHCV protease inhibitor,potent and selective<\/td>\n<\/tr>\n
A3263<\/td>\nBRAF inhibitor<\/td>\n918505-61-0<\/td>\n98.00%<\/td>\nPotent B-raf inhibitor<\/td>\n<\/tr>\n
A3264<\/td>\nB-Raf inhibitor<\/td>\n1315330-11-0<\/td>\n98.00%<\/td>\nA B-Raf inhibitor<\/td>\n<\/tr>\n
A3265<\/td>\nBrassinolide<\/td>\n72962-43-7<\/td>\n98.00%<\/td>\nPlant growth regulator<\/td>\n<\/tr>\n
A3266<\/td>\nBS-181<\/td>\n1092443-52-1<\/td>\n98.00%<\/td>\nCDK7 inhibitor,highly selective<\/td>\n<\/tr>\n
A3268<\/td>\nCAL-130 Hydrochloride<\/td>\n1431697-78-7<\/td>\n98.00%<\/td>\nPI3K inhibitor<\/td>\n<\/tr>\n
A3270<\/td>\nCalcifediol monohydrate<\/td>\n63283-36-3<\/td>\n99.43%<\/td>\nPrehormone;vitamin D3 metabolite<\/td>\n<\/tr>\n
A3271<\/td>\nCalcipotriol<\/td>\n112965-21-6<\/td>\n98.00%<\/td>\nVitamin D3 analog,regulates cell differentiation and proliferation<\/td>\n<\/tr>\n
A3275<\/td>\nCalcium-Sensing Receptor Antagonists I<\/td>\n478963-79-0<\/td>\n98.00%<\/td>\nCaSR antagonist<\/td>\n<\/tr>\n
A3276<\/td>\nCanertinib dihydrochloride<\/td>\n289499-45-2<\/td>\n99.72%<\/td>\nPan-ErbB inhibitor, potent and selective<\/td>\n<\/tr>\n
A3277<\/td>\nCapadenoson<\/td>\n544417-40-5<\/td>\n98.00%<\/td>\nAdenosine A1 receptor agonist<\/td>\n<\/tr>\n
A3278<\/td>\nNonivamide (Capsaicin Analog)<\/td>\n2444-46-4<\/td>\n99.53%<\/td>\nTRPV1 receptor agonist<\/td>\n<\/tr>\n
A3279<\/td>\nCapsazepine<\/td>\n138977-28-3<\/td>\n99.25%<\/td>\nTRPV1 ion channel antagonist<\/td>\n<\/tr>\n
A3282<\/td>\nCariprazine<\/td>\n839712-12-8<\/td>\n99.19%<\/td>\nD2\/D3 partial agonist,antipsychotic drug<\/td>\n<\/tr>\n
A3284<\/td>\nCathepsin S inhibitor<\/td>\n1373215-15-6<\/td>\n98.33%<\/td>\nBlocks MHCII antigen presentation<\/td>\n<\/tr>\n
A3285<\/td>\nCB 300919<\/td>\n289715-28-2<\/td>\n98.00%<\/td>\nPotential therapy for ovarian cancer<\/td>\n<\/tr>\n
A3286<\/td>\nCB30865<\/td>\n206275-15-2<\/td>\n98.00%<\/td>\nNampt inhibitor<\/td>\n<\/tr>\n
A3287<\/td>\nCC-401 hydrochloride<\/td>\n1438391-30-0<\/td>\n98.00%<\/td>\nJNK inhibitor<\/td>\n<\/tr>\n
A3288<\/td>\nCC-930<\/td>\n899805-25-5<\/td>\n98.00%<\/td>\nJNK inhibitor,potent and selective<\/td>\n<\/tr>\n
A3289<\/td>\nCCG-63802<\/td>\n620112-78-9<\/td>\n98.00%<\/td>\nRGS protein inhibitor<\/td>\n<\/tr>\n
A3290<\/td>\nCCG-63808<\/td>\n620113-73-7<\/td>\n98.00%<\/td>\nReversible RGS inhibitor<\/td>\n<\/tr>\n
A3291<\/td>\nCCT241533<\/td>\n1262849-73-9<\/td>\n98.00%<\/td>\nPotent Chk2 inhibitor<\/td>\n<\/tr>\n
A3292<\/td>\nCCT241533 hydrochloride<\/td>\n1431697-96-9<\/td>\n98.00%<\/td>\nCHK2 kinase inhibitor, novel<\/td>\n<\/tr>\n
A3293<\/td>\nCDK inhibitor II<\/td>\n1269815-17-9<\/td>\n98.00%<\/td>\nCDK inhibitor<\/td>\n<\/tr>\n
A3294<\/td>\nCDK9 inhibitor<\/td>\n1415559-43-1<\/td>\n98.00%<\/td>\nCDK9 inhibitor<\/td>\n<\/tr>\n
A3295<\/td>\nCDK9 inhibitor 2<\/td>\n1263369-28-3<\/td>\n98.00%<\/td>\nCDK9 inhibitor<\/td>\n<\/tr>\n
A3297<\/td>\nCEP-32496 hydrochloride<\/td>\n1227678-26-3<\/td>\n98.00%<\/td>\nB-Raf\/C-Raf inhibitor,highly potent<\/td>\n<\/tr>\n
A3297<\/td>\nCEP-32496 hydrochloride<\/td>\n1227678-26-3<\/td>\n98.00%<\/td>\nB-Raf\/C-Raf inhibitor,highly potent<\/td>\n<\/tr>\n
A3298<\/td>\nCetirizine<\/td>\n83881-51-0<\/td>\n99.65%<\/td>\nAntihistamine<\/td>\n<\/tr>\n
A3300<\/td>\nCevimeline hydrochloride hemihydrate<\/td>\n153504-70-2<\/td>\n98.00%<\/td>\nAgonist of muscarinic receptor (M1\/M3)<\/td>\n<\/tr>\n
A3302<\/td>\nCGI-1746<\/td>\n910232-84-7<\/td>\n98.00%<\/td>\nBtk inhibitor<\/td>\n<\/tr>\n
A3303<\/td>\nCGP60474<\/td>\n164658-13-3<\/td>\n98.00%<\/td>\nCDKs and PKC inhibitor, potent<\/td>\n<\/tr>\n
A3304<\/td>\nCGS 21680<\/td>\n120225-54-9<\/td>\n98.00%<\/td>\nAdenosine A2 receptor agonists,potent and selective<\/td>\n<\/tr>\n
A3305<\/td>\nCHAPS<\/td>\n75621-03-3<\/td>\n97.71%<\/td>\nZwitterionic detergent for membrane proteins,nondenaturing<\/td>\n<\/tr>\n
A3306<\/td>\nChelerythrine Chloride<\/td>\n3895-92-9<\/td>\n99.36%<\/td>\nPKC antagonist<\/td>\n<\/tr>\n
A3307<\/td>\nCHIR-090<\/td>\n728865-23-4<\/td>\n99.37%<\/td>\nPotent LpxC inhibitor<\/td>\n<\/tr>\n
A3308<\/td>\nCholine Fenofibrate<\/td>\n856676-23-8<\/td>\n99.92%<\/td>\nCholine salt of fenofibric acid<\/td>\n<\/tr>\n
A3309<\/td>\nCHR-6494<\/td>\n1333377-65-3<\/td>\n98.00%<\/td>\nHaspin inhibitor,potent ands selective<\/td>\n<\/tr>\n
A3310<\/td>\nchroman 1<\/td>\n1273579-40-0<\/td>\n98.00%<\/td>\nROCK II inhibitor, highly potent and selective<\/td>\n<\/tr>\n
A3311<\/td>\nCID-2858522<\/td>\n758679-97-9<\/td>\n98.00%<\/td>\nNF-\u03baB pathway inhibitor<\/td>\n<\/tr>\n
A3313<\/td>\nCinacalcet<\/td>\n226256-56-0<\/td>\n99.48%<\/td>\nCalcimimetic agent,orally active<\/td>\n<\/tr>\n
A3314<\/td>\nCinaciguat<\/td>\n329773-35-5<\/td>\n98.00%<\/td>\nSoluble guanylate cyclase (sGC) activators<\/td>\n<\/tr>\n
A3315<\/td>\nClemizole<\/td>\n442-52-4<\/td>\n99.06%<\/td>\nH1 histamine receptor antagonist<\/td>\n<\/tr>\n
A3316<\/td>\nClemizole hydrochloride<\/td>\n1163-36-6<\/td>\n99.73%<\/td>\nH1 histamine receptor antagonist<\/td>\n<\/tr>\n
A3317<\/td>\nClozapine N-oxide (CNO)<\/td>\n34233-69-7<\/td>\n99.74%<\/td>\nMetabolite of clozapine, used in chemogenetics.<\/td>\n<\/tr>\n
A3319<\/td>\nCMK<\/td>\n821794-90-5<\/td>\n98.00%<\/td>\nRSK2 kinase inhibitor<\/td>\n<\/tr>\n
A3320<\/td>\nCO-1686 (AVL-301)<\/td>\n1374640-70-6<\/td>\n99.28%<\/td>\nEGFR inhibitor<\/td>\n<\/tr>\n
A3321<\/td>\nCobimetinib<\/td>\n934660-93-2<\/td>\n99.71%<\/td>\nSelective MEK inhibitor<\/td>\n<\/tr>\n
A3322<\/td>\nCobimetinib (racemate)<\/td>\n934662-91-6<\/td>\n98.00%<\/td>\nSelective MEK inhibitor<\/td>\n<\/tr>\n
A3331<\/td>\nCP-809101 hydrochloride<\/td>\n1215721-40-6<\/td>\n98.00%<\/td>\n5-HT2C receptor agonist, potent and selective<\/td>\n<\/tr>\n
A3334<\/td>\nCTS-1027<\/td>\n193022-04-7<\/td>\n98.00%<\/td>\nMMPs inhibitor<\/td>\n<\/tr>\n
A3335<\/td>\nCurcumin<\/td>\n458-37-7<\/td>\n98.36%<\/td>\nTyrosinase inhibitor<\/td>\n<\/tr>\n
A3336<\/td>\nCVT-313<\/td>\n199986-75-9<\/td>\n98.04%<\/td>\nCdk2 inhibitor<\/td>\n<\/tr>\n
A3337<\/td>\nCX-6258<\/td>\n1202916-90-2<\/td>\n98.28%<\/td>\nPan-Pim kinases Inhibitor<\/td>\n<\/tr>\n
A3339<\/td>\nCYT387 sulfate salt<\/td>\n1056636-06-6<\/td>\n98.00%<\/td>\nJAK1\/JAK2 inhibitor<\/td>\n<\/tr>\n
A3340<\/td>\nCZC24832<\/td>\n1159824-67-5<\/td>\n98.00%<\/td>\nSelective PI3K-\u03b3 inhibitor<\/td>\n<\/tr>\n
A3342<\/td>\nD4476<\/td>\n301836-43-1<\/td>\n99.22%<\/td>\nCK1\/ALK5 inhibitor,specific and cell permeable<\/td>\n<\/tr>\n
A3343<\/td>\nD609<\/td>\n83373-60-8<\/td>\n98.00%<\/td>\nPC-PLC inhibitor<\/td>\n<\/tr>\n
A3344<\/td>\nD-64131<\/td>\n74588-78-6<\/td>\n98.00%<\/td>\nTubulin polymerization inhibitor<\/td>\n<\/tr>\n
A3345<\/td>\nDabigatran etexilate mesylate<\/td>\n872728-81-9<\/td>\n99.41%<\/td>\nDirect thrombin inhibitor,anticoagulant,prodrug of dabigatran<\/td>\n<\/tr>\n
A3346<\/td>\nDabigatran ethyl ester<\/td>\n429658-95-7<\/td>\n98.00%<\/td>\nThrombin activity inhibitor<\/td>\n<\/tr>\n
A3347<\/td>\nDabrafenib Mesylate (GSK-2118436)<\/td>\n1195768-06-9<\/td>\n99.78%<\/td>\nInhibitor of BRAF(V600) mutants<\/td>\n<\/tr>\n
A3348<\/td>\nDaminozide<\/td>\n1596-84-5<\/td>\n98.00%<\/td>\nKDM2A inhibitor<\/td>\n<\/tr>\n
A3349<\/td>\nDarapladib<\/td>\n356057-34-6<\/td>\n99.54%<\/td>\nLp-PLA2 inhibitor, selective and orally active<\/td>\n<\/tr>\n
A3351<\/td>\nDasatinib hydrochloride<\/td>\n854001-07-3<\/td>\n99.91%<\/td>\nMulti-BCR\/Abl and Src kinase inhibitor, oral active<\/td>\n<\/tr>\n
A3352<\/td>\nDaun02<\/td>\n290304-24-4<\/td>\n98.00%<\/td>\nCell viability inhibitor,DNA synthisis inhibitor<\/td>\n<\/tr>\n
A3353<\/td>\nDB07268<\/td>\n929007-72-7<\/td>\n98.84%<\/td>\nJNK1 inhibitor<\/td>\n<\/tr>\n
A3355<\/td>\nDeferasirox Fe3+ chelate<\/td>\n554435-83-5<\/td>\n98.00%<\/td>\nOral iron chelator<\/td>\n<\/tr>\n
A3356<\/td>\nDelafloxacin<\/td>\n189279-58-1<\/td>\n99.81%<\/td>\nFluoroquinolone antibiotic<\/td>\n<\/tr>\n
A3357<\/td>\nDelafloxacin meglumine<\/td>\n352458-37-8<\/td>\n98.00%<\/td>\nFluoroquinolone antibiotic agent<\/td>\n<\/tr>\n
A3358<\/td>\nDeltarasin<\/td>\n1440898-61-2<\/td>\n98.00%<\/td>\nKRAS-PDE\u03b4 interaction inhibitor<\/td>\n<\/tr>\n
A3359<\/td>\nDesmopressin<\/td>\n16679-58-6<\/td>\n98.66%<\/td>\nHemostatic and anti-diuretic<\/td>\n<\/tr>\n
A3360<\/td>\nDesmopressin Acetate<\/td>\n62288-83-9<\/td>\n98.73%<\/td>\nSynthetic analogue of arginine vasopressin<\/td>\n<\/tr>\n
A3363<\/td>\nDGAT-1 inhibitor<\/td>\n701232-20-4<\/td>\n99.64%<\/td>\nDiacylglycerol acyltransferase (DGAT1) inhibitor<\/td>\n<\/tr>\n
A3366<\/td>\nDipraglurant<\/td>\n872363-17-2<\/td>\n98.00%<\/td>\nmGluR5 antagonist<\/td>\n<\/tr>\n
A3368<\/td>\nDMAT<\/td>\n749234-11-5<\/td>\n98.60%<\/td>\nCK2 inhibitor,potent and selective<\/td>\n<\/tr>\n
A3369<\/td>\nDMP 777<\/td>\n157341-41-8<\/td>\n98.00%<\/td>\nLeukocyte elastase (HLE) inhibitor<\/td>\n<\/tr>\n
A3370<\/td>\nDocetaxel Trihydrate<\/td>\n148408-66-6<\/td>\n99.78%<\/td>\nDepolymerisation of microtubules inhibitor<\/td>\n<\/tr>\n
A3371<\/td>\nDoramectin<\/td>\n117704-25-3<\/td>\n97.08%<\/td>\nAntiparasitic antibiotic<\/td>\n<\/tr>\n
A3374<\/td>\nDronedarone<\/td>\n141626-36-0<\/td>\n99.58%<\/td>\nCYP3A4 and 2D6 inhibitor,moderate<\/td>\n<\/tr>\n
A3375<\/td>\nDY131<\/td>\n95167-41-2<\/td>\n99.82%<\/td>\nERR\u03b3 agonist<\/td>\n<\/tr>\n
A3378<\/td>\nE-3810<\/td>\n1058137-23-7<\/td>\n98.00%<\/td>\nVEGF\/FGF dual inhibitor, potent and selective<\/td>\n<\/tr>\n
A3380<\/td>\nEbrotidine<\/td>\n100981-43-9<\/td>\n98.00%<\/td>\nH2-receptor antagonist,competitive<\/td>\n<\/tr>\n
A3381<\/td>\nEdoxaban<\/td>\n480449-70-5<\/td>\n99.27%<\/td>\nFactor Xa inhibitor<\/td>\n<\/tr>\n
A3383<\/td>\nEdoxaban tosylate monohydrate<\/td>\n1229194-11-9<\/td>\n99.34%<\/td>\nOral factor Xa inhibitor<\/td>\n<\/tr>\n
A3384<\/td>\nElacridar<\/td>\n143664-11-3<\/td>\n98.17%<\/td>\nBCRP inhibitor<\/td>\n<\/tr>\n
A3385<\/td>\nElacridar hydrochloride<\/td>\n143851-98-3<\/td>\n98.00%<\/td>\nBCRP and P-GP inhibitor<\/td>\n<\/tr>\n
A3387<\/td>\nEltrombopag Olamine<\/td>\n496775-62-3<\/td>\n98.49%<\/td>\nC-mpl agonist<\/td>\n<\/tr>\n
A3389<\/td>\nEMD638683<\/td>\n1181770-72-8<\/td>\n98.46%<\/td>\nSGK1 inhibitor<\/td>\n<\/tr>\n
A3392<\/td>\nEmodin<\/td>\n518-82-1<\/td>\n99.09%<\/td>\nNaturally occurring anthraquinone,antiproliferative<\/td>\n<\/tr>\n
A3394<\/td>\nEpothilone D<\/td>\n189453-10-9<\/td>\n98.00%<\/td>\nNatural polyketide compound<\/td>\n<\/tr>\n
A3395<\/td>\nErcalcidiol<\/td>\n21343-40-8<\/td>\n98.00%<\/td>\nVitamin D2 metabolite,ligand of VDR-like receptors<\/td>\n<\/tr>\n
A3396<\/td>\nErcalcitriol<\/td>\n60133-18-8<\/td>\n98.00%<\/td>\nActive metabolite of vitamin D2<\/td>\n<\/tr>\n
A3397<\/td>\nErlotinib<\/td>\n183321-74-6<\/td>\n99.47%<\/td>\nEGFR tyrosine kinase inhibitor<\/td>\n<\/tr>\n
A3399<\/td>\nEsomeprazole Magnesium trihydrate<\/td>\n217087-09-7<\/td>\n98.32%<\/td>\nProton pump inhibitor<\/td>\n<\/tr>\n
A3401<\/td>\nEtifoxine hydrochloride<\/td>\n56776-32-0<\/td>\n99.87%<\/td>\nGABAA receptor potentiator<\/td>\n<\/tr>\n
A3403<\/td>\nEtofenamate<\/td>\n30544-47-9<\/td>\n98.05%<\/td>\nNon-steroidal anti-inflammatory drug<\/td>\n<\/tr>\n
A3404<\/td>\nEtomoxir<\/td>\n124083-20-1<\/td>\n99.75%<\/td>\n(CPT)-1 and DGAT activity inhibitor<\/td>\n<\/tr>\n
A3405<\/td>\nEtoricoxib<\/td>\n202409-33-4<\/td>\n99.82%<\/td>\nSpecific COX-2 inhibitor<\/td>\n<\/tr>\n
A3407<\/td>\nEVP-6124 hydrochloride<\/td>\n550999-74-1<\/td>\n99.85%<\/td>\nAlpha7 nAChR agonist<\/td>\n<\/tr>\n
A3408<\/td>\nExendin-4<\/td>\n141758-74-9<\/td>\n99.66%<\/td>\nGLP-1 activator<\/td>\n<\/tr>\n
A3411<\/td>\nFaropenem daloxate<\/td>\n141702-36-5<\/td>\n98.00%<\/td>\nOral penem,beta-lactam antibiotic<\/td>\n<\/tr>\n
A3412<\/td>\nFenretinide<\/td>\n65646-68-6<\/td>\n98.00%<\/td>\nSynthetic retinoid agonist<\/td>\n<\/tr>\n
A3413<\/td>\nFH535<\/td>\n108409-83-2<\/td>\n99.62%<\/td>\nWnt\/B-catenin inhibitor<\/td>\n<\/tr>\n
A3415<\/td>\nFirategrast<\/td>\n402567-16-2<\/td>\n99.56%<\/td>\n\u03b14\u03b21\/\u03b14\u03b27 integrin antagonist<\/td>\n<\/tr>\n
A3416<\/td>\nFK 3311<\/td>\n116686-15-8<\/td>\n98.00%<\/td>\nSelective COX-2 inhibitor<\/td>\n<\/tr>\n
A3417<\/td>\nFlavopiridol<\/td>\n146426-40-6<\/td>\n99.52%<\/td>\nPan-cdk inhibitor<\/td>\n<\/tr>\n
A3418<\/td>\nFlecainide acetate<\/td>\n54143-56-5<\/td>\n99.82%<\/td>\nAntiarrhythmic drug<\/td>\n<\/tr>\n
A3419<\/td>\nFluvastatin<\/td>\n93957-54-1<\/td>\n98.33%<\/td>\nHMGCR inhibitor<\/td>\n<\/tr>\n
A3420<\/td>\nFMK<\/td>\n821794-92-7<\/td>\n98.82%<\/td>\nRSK inhibitor<\/td>\n<\/tr>\n
A3421<\/td>\nFosamprenavir Calcium Salt<\/td>\n226700-81-8<\/td>\n99.71%<\/td>\nProdrug of antiretroviral protease inhibitor amprenavir<\/td>\n<\/tr>\n
A3423<\/td>\nGalanthamine<\/td>\n357-70-0<\/td>\n99.12%<\/td>\nAcetylcholinesterase inhibitor<\/td>\n<\/tr>\n
A3424<\/td>\nGambogic Acid<\/td>\n2752-65-0<\/td>\n98.54%<\/td>\nCaspase activator and apoptosis inducer<\/td>\n<\/tr>\n
A3429<\/td>\nGANT 58<\/td>\n64048-12-0<\/td>\n99.38%<\/td>\nGLI antagonist,novel and potent<\/td>\n<\/tr>\n
A3432<\/td>\nGDC-0941 dimethanesulfonate<\/td>\n957054-33-0<\/td>\n99.78%<\/td>\nPI3K inhibitor<\/td>\n<\/tr>\n
A3433<\/td>\nGefitinib hydrochloride<\/td>\n184475-55-6<\/td>\n99.87%<\/td>\nPotent EGFR inhibitor<\/td>\n<\/tr>\n
A3434<\/td>\nGenz-644282<\/td>\n529488-28-6<\/td>\n98.00%<\/td>\nNon-camptothecin inhibitor of topoisomerase I<\/td>\n<\/tr>\n
A3435<\/td>\nglucagon receptor antagonists 1<\/td>\n503559-84-0<\/td>\n98.00%<\/td>\nGlucagon receptor antagonist,highly potent<\/td>\n<\/tr>\n
A3436<\/td>\nglucagon receptor antagonists 2<\/td>\n202917-18-8<\/td>\n98.00%<\/td>\nGlucagon receptor antagonist,highly potent<\/td>\n<\/tr>\n
A3437<\/td>\nglucagon receptor antagonists 3<\/td>\n202917-17-7<\/td>\n98.00%<\/td>\nGlucagon receptor antagonist<\/td>\n<\/tr>\n
A3438<\/td>\nGlucocorticoid receptor agonist<\/td>\n1245526-82-2<\/td>\n98.00%<\/td>\nGlucagon receptor antagonist<\/td>\n<\/tr>\n
A3440<\/td>\nGlyoxalase I inhibitor<\/td>\n221174-33-0<\/td>\n98.00%<\/td>\nGlyoxalase I inhibitor<\/td>\n<\/tr>\n
A3441<\/td>\nGPR120 modulator 1<\/td>\n1050506-75-6<\/td>\n98.00%<\/td>\nGPR120 modulator<\/td>\n<\/tr>\n
A3442<\/td>\nGPR120 modulator 2<\/td>\n1050506-87-0<\/td>\n98.00%<\/td>\nGPR120 modulator<\/td>\n<\/tr>\n
A3443<\/td>\nGranisetron<\/td>\n109889-09-0<\/td>\n98.00%<\/td>\nSerotonin 5-HT3 receptor antagonist<\/td>\n<\/tr>\n
A3444<\/td>\nGS-9620<\/td>\n1228585-88-3<\/td>\n98.01%<\/td>\nTLR-7 agonist<\/td>\n<\/tr>\n
A3445<\/td>\nGSK 525768A<\/td>\n1260530-25-3<\/td>\n98.00%<\/td>\ninactive stereoisomer of I-BET-762<\/td>\n<\/tr>\n
A3446<\/td>\nGSK126<\/td>\n1346574-57-9<\/td>\n98.32%<\/td>\nEZH2 inhibitor<\/td>\n<\/tr>\n
A3448<\/td>\nGSK2606414<\/td>\n1337531-36-8<\/td>\n98.18%<\/td>\nPERK inhibitor,potent and selective<\/td>\n<\/tr>\n
A3449<\/td>\nGSK343<\/td>\n1346704-33-3<\/td>\n98.95%<\/td>\nEZH2 inhibitor,potent,selective and cell permeable<\/td>\n<\/tr>\n
A3450<\/td>\nGSK-923295<\/td>\n1088965-37-0<\/td>\n98.28%<\/td>\nCENP-E inhibitor,small-molecule<\/td>\n<\/tr>\n
A3451<\/td>\nGuanfacine hydrochloride<\/td>\n29110-48-3<\/td>\n99.41%<\/td>\n\u03b12A-adrenoceptor agonist<\/td>\n<\/tr>\n
A3452<\/td>\nGW-1100<\/td>\n306974-70-9<\/td>\n98.00%<\/td>\nGPR40 antagonist<\/td>\n<\/tr>\n
A3453<\/td>\nGW1929<\/td>\n196808-24-9<\/td>\n98.00%<\/td>\nPotent PPAR\u03b3 agonist<\/td>\n<\/tr>\n
A3454<\/td>\nGW3965<\/td>\n405911-09-3<\/td>\n98.00%<\/td>\nHLXR\u03b1\/hLXR\u03b2 agonist,potent and selective<\/td>\n<\/tr>\n
A3456<\/td>\nGW843682X<\/td>\n660868-91-7<\/td>\n98.00%<\/td>\nPLK1\/PLK3 inhibitor,potent and selective<\/td>\n<\/tr>\n
A3460<\/td>\nHhAntag<\/td>\n496794-70-8<\/td>\n98.95%<\/td>\nGLI1-mediated transcription inhibitor<\/td>\n<\/tr>\n
A3461<\/td>\nHIV-1 integrase inhibitor<\/td>\n544467-07-4<\/td>\n98.00%<\/td>\nUesful for anti-HIV<\/td>\n<\/tr>\n
A3465<\/td>\nHOE 33187<\/td>\n23623-08-7<\/td>\n98.00%<\/td>\nBlue fluorescent dyes<\/td>\n<\/tr>\n
A3466<\/td>\nHoechst 33258<\/td>\n23491-45-4<\/td>\n99.88%<\/td>\nBlue fluorescent dyes<\/td>\n<\/tr>\n
A3472<\/td>\nHoechst 33342<\/td>\n875756-97-1<\/td>\n98.84%<\/td>\nBlue fluorescent dyes<\/td>\n<\/tr>\n
A3475<\/td>\nHoechst 34580<\/td>\n23555-00-2<\/td>\n97.70%<\/td>\nBlue fluorescent dyes<\/td>\n<\/tr>\n
A3477<\/td>\nHOKU-81<\/td>\n58020-43-2<\/td>\n98.00%<\/td>\nBronchodilators,metabolite of tulobuterol<\/td>\n<\/tr>\n
A3478<\/td>\nHydroxyfasudil<\/td>\n105628-72-6<\/td>\n98.00%<\/td>\nRho-kinase inhibitor and vasodilator<\/td>\n<\/tr>\n
A3479<\/td>\nHydroxyfasudil hydrochloride<\/td>\n155558-32-0<\/td>\n98.71%<\/td>\nRho-kinase inhibitor and vasodilator<\/td>\n<\/tr>\n
A3481<\/td>\nIbutamoren Mesylate<\/td>\n159752-10-0<\/td>\n98.00%<\/td>\nGrowth hormone (GH) secretagogue<\/td>\n<\/tr>\n
A3482<\/td>\nIcotinib Hydrochloride<\/td>\n1204313-51-8<\/td>\n98.00%<\/td>\nEGFR inhibitor,potent and specific<\/td>\n<\/tr>\n
A3483<\/td>\nIDO inhibitor 1<\/td>\n1204669-37-3<\/td>\n99.83%<\/td>\nIndoleamine-2,3-dioxygenase inhibitor<\/td>\n<\/tr>\n
A3484<\/td>\nIguratimod<\/td>\n123663-49-0<\/td>\n98.00%<\/td>\nCOX-2 inhibitor,inhibits IL-1,IL-6,IL-8 and tumour necrosis factor.<\/td>\n<\/tr>\n
A3485<\/td>\nIKK-2 inhibitor VIII<\/td>\n406209-26-5<\/td>\n98.00%<\/td>\nIKK-2 inhibitor,potent and selective<\/td>\n<\/tr>\n
A3486<\/td>\nIKK-3 Inhibitor<\/td>\n862812-98-4<\/td>\n98.00%<\/td>\nIKK-3 Inhibitor<\/td>\n<\/tr>\n
A3487<\/td>\nImatinib hydrochloride<\/td>\n862366-25-4<\/td>\n98.00%<\/td>\nV-Abl\/c-Kit\/PDGFR inhibitor<\/td>\n<\/tr>\n
A3492<\/td>\nINCB 3284 dimesylate<\/td>\n887401-93-6<\/td>\n98.00%<\/td>\nHCCR2 antagonist<\/td>\n<\/tr>\n
A3493<\/td>\nINCB024360 analogue<\/td>\n914471-09-3<\/td>\n99.81%<\/td>\npotent and selective inhibitor of IDO1<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

MAPK\/ERK Pathway\u7cfb\u5217\u5546\u54c1->>p-Cresyl sulfate APExBIO T […]<\/p>\n","protected":false},"author":3,"featured_media":47343,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[5368],"tags":[],"_links":{"self":[{"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/54750"}],"collection":[{"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=54750"}],"version-history":[{"count":1,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/54750\/revisions"}],"predecessor-version":[{"id":54751,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/posts\/54750\/revisions\/54751"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=\/wp\/v2\/media\/47343"}],"wp:attachment":[{"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=54750"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=54750"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/biopioneer.com.tw\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=54750"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}